<SEC-DOCUMENT>0001193125-20-307387.txt : 20201201
<SEC-HEADER>0001193125-20-307387.hdr.sgml : 20201201
<ACCEPTANCE-DATETIME>20201201172823
ACCESSION NUMBER:		0001193125-20-307387
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20201201
DATE AS OF CHANGE:		20201201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adicet Bio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-229499
		FILM NUMBER:		201361755

	BUSINESS ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		500 BOYLSTON STREET
		STREET 2:		12TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	resTORbio, Inc.
		DATE OF NAME CHANGE:	20171024
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d32534d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5) <BR> Registration No. 333-229499 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT&nbsp;&nbsp;&nbsp;&nbsp; </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(To
Prospectus dated February&nbsp;12, 2019) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Up to $50,000,000 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g32534g44y02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into a sales
agreement with Evercore Group L.L.C., or Evercore, and H.C. Wainwright&nbsp;&amp; Co., LLC, or Wainwright, each an Agent and collectively, the Agents, relating to shares of our common stock offered by this prospectus supplement. In accordance with
the terms of the sales agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $50,000,000 from time to time through the Agents, acting as agents or principals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Market under the symbol &#147;ACET.&#148; On November&nbsp;30, 2020, the closing price of our common stock, as
reported on The Nasdaq Global Market, was $12.33 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of our common stock, if any, under this prospectus supplement will be made in sales
deemed to be &#147;at the market offerings&#148; as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, or the Securities Act. The Agents are not required to sell any specific amount of securities, but will act as our sales
agents using commercially reasonable efforts consistent with their normal trading and sales practices, on mutually agreed terms between the Agents and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The compensation to the Agents for sales of common stock sold pursuant to the sales agreement will be an amount equal to 3.0% of the gross proceeds of
any shares of common stock sold under the sales agreement. In connection with the sale of the common stock on our behalf, each Agent will be deemed to be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of
each Agent will be deemed to be underwriting commissions or discounts. We have also agreed to provide indemnification and contribution to the Agents with respect to certain liabilities, including liabilities under the Securities Act or the
Securities Exchange Act of 1934, as amended, or the Exchange Act. See the section titled &#147;Plan of Distribution&#148; on page <FONT STYLE="white-space:nowrap">S-25</FONT> of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an emerging growth company as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain
reduced public company reporting requirements for this prospectus supplement, the accompanying prospectus and future filings. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our common
stock involves a high degree of risk. You should review carefully the risks and uncertainties referenced under the heading &#147;<A HREF="#supprom32534_4">Risk Factors</A>&#148; on page <FONT STYLE="white-space:nowrap">S-8</FONT> of this prospectus
supplement and in the documents that are incorporated by reference into this prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:16pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:16pt">
<TD VALIGN="top" NOWRAP><B>Evercore ISI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="right"><B>H.C. Wainwright&nbsp;&amp; Co.</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is December&nbsp;1, 2020 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom32534_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-i</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom32534_2">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-iii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom32534_3">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom32534_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom32534_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom32534_6">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-15</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom32534_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-16</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom32534_8">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-18</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom32534_9">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-22</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom32534_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-25</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom32534_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom32534_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom32534_13">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom32534_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_3">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_4">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_6">SECURITIES WE MAY OFFER OR THAT A SELLING STOCKHOLDER MAY
OFFER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_7">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_8">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_9">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_10">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_11">SELLING STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_12">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_13">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_14">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_15">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_16">INCORPORATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom32534_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document is part of the registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a &#147;shelf&#148;
registration process and consists of two parts. The first part is this prospectus supplement, including the documents incorporated by reference, which describes the specific terms of this offering. The second part, the accompanying prospectus dated
February&nbsp;12, 2019, included in our registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-229499)</FONT> including the documents incorporated by reference, gives more
general information, some of which may not apply to this offering. Generally, when we refer to the &#147;prospectus,&#148; we are referring to both parts combined. This prospectus supplement and any related free writing prospectus we authorize for
use in connection with this offering may add to, update or change information in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement or the accompanying prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities we are offering. You should read this prospectus together with the additional
information described under the heading &#147;Where You Can Find Additional Information&#148; beginning on page <FONT STYLE="white-space:nowrap">S-26</FONT> of this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus describes the terms of this offering of common stock and also adds to and updates information contained in the documents incorporated by
reference into this prospectus. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference into this prospectus that was filed with
the SEC, before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for
example, a document incorporated by reference into this prospectus&#151;the statement in the document having the later date modifies or supersedes the earlier statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in or incorporated by reference in this prospectus or in any related free writing prospectus filed by us
with the SEC. We have not, and the agents have not, authorized anyone to provide you with different information. This prospectus does not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities
described in this prospectus or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, the
documents incorporated by reference and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not, and the Agents have not, authorized anyone to provide you with information in addition to or different from that contained in this prospectus and
any related free writing prospectus. We take no responsibility for, and can provide no assurances as to the reliability of, any information not contained in this prospectus or any related free writing prospectus that we may authorize to be provided
to you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. You should assume that the information in this prospectus or any related free writing
prospectus is accurate only as of the date on the front of the document and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this
prospectus or any related free writing prospectus, or any sale of a security. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, information contained in or incorporated by
reference into this prospectus concerning our industry and the markets in which we operate, including market opportunity, market position and competitive landscape, is based on information from our management&#146;s estimates, as well as from
industry publications, surveys and studies conducted by third parties. Management estimates are derived from publicly available information, our knowledge of our industry, and assumptions based on such information and knowledge, which we believe to
be reasonable. In addition, while we believe that information contained in the industry publications, surveys and studies has been obtained from reliable sources, the accuracy and completeness of such information is not guaranteed, and we have not
independently verified any of the data contained in these third-party sources. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus, and any documents incorporated by reference
herein or therein, include statements that are based on various assumptions and estimates that are subject to numerous known and unknown risks and uncertainties. Some of these risks and uncertainties are described under the heading &#147;Risk
Factors&#148; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-8</FONT> of this prospectus supplement and in the section titled &#147;Risk Factors&#148; in our most recent Annual Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> and Quarterly Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q,</FONT> which are incorporated by reference into the prospectus. These and other important factors could cause our future
results to be materially different from the results expected as a result of, or implied by, these assumptions and estimates. You should read the information contained in this prospectus supplement and the accompanying prospectus, and the documents
incorporated by reference herein and therein, completely and with the understanding that future results may be materially different and worse from what we expect. See the information included under the heading &#147;Cautionary Statement Regarding
Forward-Looking Statements.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to
any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreement, and should not be deemed to be
a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately
representing the current state of our affairs. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the context otherwise indicates, references in this prospectus to &#147;Adicet&#148;, &#147;Adicet
Bio,&#148; &#147;we&#148;, &#147;our&#148;, &#147;us&#148; and &#147;the Company&#148; refer, collectively, to Adicet Bio, Inc. and, where appropriate, our consolidated subsidiaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom32534_2"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus and the information incorporated by reference herein and therein contain and
any free writing prospects we authorize for use in connection with this offering may contain forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of
the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements about our expectations, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are
often, but are not always, made through the use of words or phrases such as &#147;may,&#148; &#147;will,&#148; &#147;could,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148;
&#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;potential,&#148; &#147;continue,&#148; and similar expressions, or the negative of these terms, or similar expressions. Accordingly, these statements
involve estimates, assumptions, risks and uncertainties which could cause actual results to differ materially from those expressed in them. We believe that it is important to communicate our future expectations to our investors. However, there may
be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement, the accompanying prospectus, and the information incorporated by reference herein and therein contain, and any
free writing prospects we authorize for use in connection with this offering may contain, forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently available to our management. These
statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated timing of our initiation of future clinical trials for
<FONT STYLE="white-space:nowrap">ADI-001</FONT> in <FONT STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> Lymphoma, or NHL, including the anticipated results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the anticipated timing of our submission of Investigational New Drug, or IND, applications or equivalent
regulatory filings and initiation of future clinical trials for <FONT STYLE="white-space:nowrap">ADI-002</FONT> in solid tumors, including the timing of the anticipated results; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impacts of the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our continuing
operations, clinical development plans, including the timing of initiation and completion of studies or trials, financial forecasts and expectations, potential delays and increased costs in conducting clinical trials in nursing homes, and other
matters related to our business and operations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of acceptance and clinical utility of any products for which we receive regulatory approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify additional product candidates with significant commercial potential;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to enter into collaborations for the development and commercialization of product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of any future collaboration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to contract with third party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to retain the continued service of our key professionals and to identify, hire, and retain additional
qualified professionals; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our financial performance; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations related to the use of cash, cash equivalents and marketable securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to remediate the material weaknesses in internal control over financial reporting and to maintain
effective internal control over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government laws and regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements are neither promises nor guarantees of future performance due to a variety of risks and uncertainties, many
of which are beyond our control, which could cause actual results to differ materially from those indicated by these forward-looking statements, including, without limitation, the risk factors and cautionary statements described in other documents
that we file from time to time with the SEC, specifically under &#147;Item 1A: Risk Factors&#148; and elsewhere in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> and under similar headings in subsequent Quarterly
Reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and the section of the prospectus supplement titled &#147;Risk Factors.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus supplement, the accompanying prospectus, and the information incorporated by reference herein and therein,
completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements in this prospectus supplement and the documents we incorporate by reference herein represent our
views as of their respective dates. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current
intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-iv </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom32534_3"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights certain information about us, this offering and selected information contained elsewhere or incorporated by
reference in this prospectus supplement and the accompanying prospectus. This summary is not complete and does not contain all the information that you should consider before making your investment decision. You should read this entire prospectus
supplement and the accompanying prospectus carefully, especially the risks of investing in our securities discussed under &#147;Risk Factors&#148; beginning on <FONT STYLE="white-space:nowrap">page&nbsp;S-8</FONT> of this prospectus supplement,
along with our financial statements and related notes and the other information incorporated by reference into this prospectus supplement and the accompanying prospectus and any free writing prospectus we authorize for use in connection with this
offering, before making an investment decision. This prospectus supplement may add to, update or change information in the accompanying prospectus. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a biotechnology company
discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet is advancing a pipeline of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;off-the-shelf&#148;</FONT></FONT> gamma delta
T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. We
believe our approach has potentially significant advantages over alpha beta T cells, which are the basis of standard chimeric antigen receptor, or <FONT STYLE="white-space:nowrap">CAR,-T</FONT> cell therapies. We are developing proprietary processes
for engineering and manufacturing product candidates based on gamma delta T cells from the blood of healthy donors, resulting in high yields of cells with efficacious tumor-killing activity in preclinical studies. The potential to administer product
candidates based on gamma delta T cells to patients without inducing a graft versus host immune response could mean that our products can potentially be produced as
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;off-the-shelf&#148;</FONT></FONT> therapies. This is in contrast to products based on alpha beta T cells, which either must be manufactured for each patient from his or her own
T cells, or require significant gene editing to manufacture if the T cells are derived from donors that are unrelated to the patient. Based on what we believe is the unique potential of these cells and associated modifications, we are initially
developing product candidates in oncology, both for hematological malignancies and for solid tumors. Due to certain unique properties of gamma delta T cells, we believe that our product candidates can be developed to have an inherent capacity to
recognize and kill circulating tumor cells and to infiltrate and kill solid tumors. In October 2020, the United States, or U.S., Food and Drug Administration, or FDA, cleared our IND application for <FONT STYLE="white-space:nowrap">ADI-001,</FONT>
our lead product candidate, for the treatment of NHL. The active IND enables us to initiate the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial to assess safety and efficacy of <FONT
STYLE="white-space:nowrap">ADI-001</FONT> in NHL patients, which it plans to initiate in the first quarter of 2021. The Phase 1 study for <FONT STYLE="white-space:nowrap">ADI-001</FONT> will enroll up to 80 late-stage
<FONT STYLE="white-space:nowrap">non-Hodgkin&#146;s</FONT> lymphoma patients at a number of cancer centers across the U.S. The study includes a dose finding portion followed by dose expansion cohorts to explore the activity of <FONT
STYLE="white-space:nowrap">ADI-001</FONT> in multiple subtypes of NHL. Site initiation activities are underway and interim clinical data from this study are expected in 2021. We intend to file an IND with the FDA in late 2021 for <FONT
STYLE="white-space:nowrap">ADI-002,</FONT> our first solid tumor product candidate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Gamma delta T cells have unique attributes that we
believe make them especially well-suited to be used for cancer therapy. Approximately 95% of T cells in circulation are <FONT STYLE="white-space:nowrap">so-called</FONT> alpha beta T cells, named after the proteins that make up the cells&#146; T
cell receptor, or TCR. Gamma delta T cells, along with a few other cell types, make up the remaining 1% to 5% of all T cells. Distinct among immune cell populations, therapeutic candidates derived from gamma delta T cells have the following
potential attributes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">can be used
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;off-the-shelf&#148;</FONT></FONT> after being expanded from healthy donors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">are actively cytotoxic to tumor cells; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">can replicate in an appropriate and measured way after manufacture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">can locate in tissues and recognize and attack cancerous cells; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">can have their specificity for tumor cells enhanced further by the addition of a CAR; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">express both T cell and natural killer, or NK, cell receptors, facilitating both adaptive and innate antitumor
immune responses; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">can be manufactured in large numbers to facilitate the treatment of many patients and to avoid the cumbersome
nature and expense of isolating T cells from each patient. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">By contrast, approved
<FONT STYLE="white-space:nowrap">CAR-T</FONT> cell therapies, as well as the majority of <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell therapies in clinical development, are based on a different population of T cells known as alpha beta T
cells, which have the ability to attack healthy tissues if those cells are not immunologically matched to the patient. For this reason, the majority of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">alpha-beta-T-cell-derived</FONT></FONT> <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell products are custom-generated from cells isolated from each patient. Gamma delta T cells, by
contrast, do not in principle require immunological matching to be potentially administered as a part of a therapy, and therefore cells isolated from healthy donors have the potential to be administered to any patient. This enables cell therapy
product candidates based on gamma delta T cells to be manufactured in bulk and developed as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> products. In animal models and early clinical trials, gamma
delta T cells have largely not expanded in healthy tissues, indicating that they may be associated with a lower risk of life-threatening immune responses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">ADI-001</FONT> is a gamma delta <FONT STYLE="white-space:nowrap">T-cell</FONT> product candidate into which
we introduced a CAR that is designed to specifically recognize CD20, a highly expressed surface protein found on the majority of NHLs. We are developing a highly efficient and robust process to activate, engineer and manufacture product candidates
derived from peripheral blood cells of healthy donors. We are developing processes that can produce these cells in bulk under conditions that are designed to meet current Good Manufacturing Practices requirements, or cGMP, to generate an inventory
of cell product that is readily available to patients on demand at clinical sites. Gamma delta T cells engineered with anti-CD20 CAR have shown highly potent antitumor activity in preclinical models, which could lead to effective long-term control
of tumor growth. We believe that <FONT STYLE="white-space:nowrap">ADI-001</FONT> has the potential to benefit patients that have NHL while also providing clinical validation of our gamma delta <FONT STYLE="white-space:nowrap">T-cell</FONT> platform
technology. We plan to initiate the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical trial to assess safety and efficacy of <FONT STYLE="white-space:nowrap">ADI-001</FONT> in NHL patients in the
first quarter of 2021. Interim clinical data from this study are expected in 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to potentially providing access to
immunocellular therapies to a broader set of patients with hematological malignancies, we believe that our technology is well-positioned to potentially bring these therapies to patients with solid tumors.
<FONT STYLE="white-space:nowrap">ADI-002</FONT> is a gamma delta T cell product candidate containing a CAR directed against <FONT STYLE="white-space:nowrap">Glypican-3,</FONT> or GPC3, a tumor antigen that is highly expressed in hepatocellular
carcinoma, or HCC, and other tumors such as gastric cancer and squamous cell carcinoma of the lung. <FONT STYLE="white-space:nowrap">ADI-002</FONT> has shown dose-dependent antitumor activity in animal models. We intend to file an IND with the FDA
in late 2021 for <FONT STYLE="white-space:nowrap">ADI-002.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our solid tumor efforts are further complemented by our proprietary T
cell receptor-like-antibody, or TCRL, platform technology, a monoclonal antibody technology which enables the generation of CARs that are designed to recognize tumor antigens inside tumor cells, also known as intracellular proteins. We believe that
the ability to selectively bind to tumor antigens derived specifically from intracellular proteins is a critical advantage to immunocellular therapy due to the scarcity of tumor-specific surface antigens on solid tumors. Our approach to generating
CARs for some product candidates is designed to take advantage of this potential ability. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Pipeline </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g32534g96z51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a pipeline of wholly owned product candidates. As part of a five-year collaboration between us and
Regeneron Pharmaceuticals, Inc., or Regeneron, pursuant to an agreement signed in 2016, Regeneron has the option to obtain development and commercial rights for a certain number of product candidates, and we have an option to participate in the
development and commercialization of these potential products or are entitled to royalty payments by Regeneron. Immunocellular therapy product candidates developed and commercialized by us under our agreement with Regeneron will be subject to
payment of royalties to Regeneron. To date, Regeneron has not exercised an option on any of our candidates. Our pipeline of additional product candidates includes <FONT STYLE="white-space:nowrap">ADI-00x,</FONT> for which we expect to file an IND
for solid tumor indications in 2022, and an IND for solid tumor and hematological indications in 2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our objective is to be the leading biotechnology company developing oncology and other therapies based on
<FONT STYLE="white-space:nowrap">CAR-modified</FONT> gamma delta T cells. Our strategy to achieve this is as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Target clinical development, regulatory approval and commercialization of
<FONT STYLE="white-space:nowrap">ADI-001,</FONT> our lead product candidate. </B>We intend<B> </B>to achieve two key objectives with the development program for <FONT STYLE="white-space:nowrap">ADI-001:</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Bring a meaningful product to patients by developing <FONT STYLE="white-space:nowrap">ADI-001</FONT> in NHL and
demonstrating its safety and efficacy; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Validate the gamma delta T cell platform, showing both safety and efficacy of a product candidate designed from
that platform, to enable rapid application to additional potential oncology indications. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To achieve these objectives,
we hope to demonstrate in our clinical trials efficacy and safety results that are similar to or better than the currently approved autologous (manufactured from the patient&#146;s own cells) alpha-beta based
<FONT STYLE="white-space:nowrap">T-cell</FONT> therapies in similar patient populations of NHL while making the product available off the shelf. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Advance <FONT STYLE="white-space:nowrap">ADI-002</FONT> into clinical development. </B><FONT
STYLE="white-space:nowrap">ADI-002,</FONT> our lead solid tumor product candidate, is currently undergoing preclinical<B> </B>studies. We intend to file an IND with the FDA in 2021 for <FONT STYLE="white-space:nowrap">ADI-002.</FONT>
</P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
Our goal is to develop <FONT STYLE="white-space:nowrap">ADI-002,</FONT> both in monotherapy and in combination with standard of care agents, in a number of solid tumors that express high levels
of GPC3. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Continue to innovate and invest in the gamma delta T cell platform and pipeline</B>. We expect to continue to
develop product<B> </B>candidates in oncology based on the gamma delta T cell platform, using either previously validated antigens, or those that we identify and target using our TCRL technology. We may utilize additional genetic engineering and
editing technologies to further improve our products for greater cell persistence, which may lead to greater efficacy. A key strength of our gamma delta T cell therapy platform lies in our ability to target antigens of both known and unknown
potential, and devote our clinical development resources to those antigens that show the most promise in preclinical <I>in vivo</I> analyses and early human trials. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Expand and protect our intellectual property. </B>We will continue to aggressively protect the gamma delta T
cell production methodology we have developed as well as specific product candidates based on proprietary antigen-binding domains. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Potential for outpatient administration</B>. While we expect that the initial subjects treated with gamma
delta T cell-based therapy<B> </B>candidates in clinical studies will be hospitalized for a minimum of 24 hours for observation after infusion, favorable tolerability results may allow administration of such therapies in an outpatient setting. This
would represent a significant competitive advantage for gamma delta T cell-based therapies as compared to existing approved <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell therapies. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to
September&nbsp;15, 2020, we were a clinical-stage biopharmaceutical company known as resTORbio, Inc. (&#147;resTORbio&#148;) that had historically focused on developing innovative medicines that target the biology of aging, to prevent or treat <FONT
STYLE="white-space:nowrap">age-related</FONT> diseases with the potential to extend healthy lifespan. resTORbio was originally incorporated under the laws of the State of Delaware in July 2016 and commenced research and development operations in
March 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;15, 2020, we completed our business combination whereby a wholly-owned subsidiary of resTORbio, Inc. merged
with and into Adicet Bio, Inc., with Adicet Bio, Inc. surviving as a wholly-owned subsidiary of resTORbio and changing its name to Adicet Therapeutics, Inc. (the &#147;Merger&#148;). In connection with the completion of the Merger, resTORbio was
renamed Adicet Bio, Inc., or Adicet Bio. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Immediately prior to the effective time of the Merger, resTORbio effected a reverse stock split
of its common stock at a ratio of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-for-7.</FONT></FONT> At the effective time of the Merger, each outstanding share of former Adicet&#146;s capital stock was converted into the right
to receive 0.1240 shares of resTORbio common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have offices in Menlo Park, CA, and Boston, MA, located at 200 Constitution Drive,
Menlo Park, CA&nbsp;94025, and 500 Boylston Street, 13th Floor, Boston, MA 02116. Our principal executive offices are located at 500 Boylston Street, 13th Floor, Boston, MA 02116. Our telephone number is (857)
<FONT STYLE="white-space:nowrap">315-5528.</FONT> Our website is located at <I>www.adicetbio.com</I>. Our website and the information contained on, or that can be accessed through, the website will not be deemed to be incorporated by reference in,
and are not considered part of, this prospectus supplement. You should not rely on any such information in making your decision whether to purchase our common stock. Our common stock trades on the Nasdaq Global Market under the symbol
&#147;ACET&#148;. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in Section&nbsp;2(a) of the Securities Act, as modified by the JOBS Act. We are
also a &#147;smaller reporting company&#148; as defined in the Exchange Act. As an emerging </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
growth company and as a smaller reporting company we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable, in general, to public companies that
are not emerging growth companies. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">only two years of audited financial statements in addition to any required unaudited interim financial statements
with correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemption from the <FONT STYLE="white-space:nowrap">non-binding</FONT> stockholder advisory votes on executive
compensation or golden parachute arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delayed adoption of new or revised financial accounting standards until they would apply to private companies and
from compliance with any new requirements adopted by the Public Company Accounting Oversight Board, or PCAOB, requiring mandatory audit firm rotation. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will remain an emerging growth company until the earlier of (1)&nbsp;December&nbsp;31, 2023 or (2)&nbsp;the last day of the fiscal year
(a)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion, or (b)&nbsp;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700&nbsp;million as of the prior June 30th, or (3)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt
during the prior three year period. References in this prospectus supplement and the accompanying prospectus to &#147;emerging growth company&#148; shall have the meaning ascribed to it in the JOBS Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will continue to be a smaller reporting company if the Company has (i)&nbsp;less than $250&nbsp;million in market value of its shares held
by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> as of the last business day of its second fiscal quarter or (ii)&nbsp;less than $100&nbsp;million of annual revenues in its most recent fiscal year completed before the last business day of
its second fiscal quarter and a market value of its shares held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of less than $700&nbsp;million as of the last business day of its second fiscal quarter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this
prospectus supplement. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock. We have elected to avail ourselves of the exemption for the delayed adoption
of certain accounting standards and, therefore, are not subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following summary contains basic information about our common stock and the offering and is not intended to be complete. It does not
contain all of the information that may be important to you. For a more complete understanding of our common stock, you should read the section entitled &#147;Description of Capital Stock&#148; in this prospectus supplement. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock offered by us </P></TD>
<TD>Shares of our common stock having an aggregate offering price of up to $50,000,000. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Common stock to be outstanding immediately after this offering </P></TD>
<TD>Up to 23,644,787 shares (as more fully described in the notes following this table), assuming sales of 4,055,150 shares of our common stock in this offering at an offering price of $12.33 per share, which was the last reported sale price of our
common stock on The Nasdaq Global Market on November&nbsp;30, 2020. The actual number of shares issued will vary depending on how many shares of our common stock we choose to sell and the prices at which such sales occur. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Manner of offering </P></TD>
<TD>&#147;At the market offering&#148; that may be made from time to time on The Nasdaq Global Market or other existing trading market for our common stock through our sales agents, Evercore and Wainwright. See &#147;Plan of Distribution&#148; on
page <FONT STYLE="white-space:nowrap">S-25</FONT> of this prospectus supplement. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </P></TD>
<TD>Our management will retain broad discretion regarding the allocation and use of the net proceeds. We currently intend to use any net proceeds from this offering primarily to fund activities relating to the development of our product candidates <FONT
STYLE="white-space:nowrap">ADI-001</FONT> and <FONT STYLE="white-space:nowrap">ADI-002,</FONT> our internal discovery research, other pipeline candidates and to fund the continued development of our gamma delta T cell platform, working capital and
capital expenditures and for other general corporate purposes. See &#147;Use of Proceeds&#148; on page <FONT STYLE="white-space:nowrap">S-14</FONT> of this prospectus supplement. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </P></TD>
<TD>Investing in our common stock involves significant risks. See &#147;Risk Factors&#148; on page <FONT STYLE="white-space:nowrap">S-8</FONT> of this prospectus supplement and under similar headings in the documents incorporated by reference into
this prospectus supplement for a discussion of the factors you should carefully consider before deciding to invest in our common stock. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Global Market symbol </P></TD>
<TD>&#147;ACET&#148; </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All information in this prospectus supplement related to the number of shares of our common stock to be outstanding
immediately after this offering is based on 19,589,637 shares outstanding as of September&nbsp;30, 2020. This number of shares excludes the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,269,399 shares of common stock issuable upon the exercise of stock options outstanding as of September&nbsp;30,
2020 at a weighted-average exercise price of $10.49 per share; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">226,191 shares of common stock issuable upon the exercise of stock warrants outstanding as of September&nbsp;30,
2020 at a weighted-average exercise price of $11.32 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,462,006 shares of common stock reserved for future issuance under our 2018 Stock Option and Incentive Plan, or
2018 Plan, as of September&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">636,168 shares of common stock for the future issuance under our 2015 Stock Incentive Plan, or 2015 Plan, as of
September&nbsp;30, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">131,432 shares of common stock reserved for the future issuance under our 2018 Employee Stock Purchase Plan, or
2018 ESPP, as of September&nbsp;30, 2020; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">472,473 shares of common stock issuable upon the exercise of stock options issued under the 2015 Plan, 2018 Plan
and as inducement grants after September&nbsp;30, 2020 at an exercise price of $12.14 per share. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that any
of these options are exercised, new options are issued under our equity incentive plans and subsequently exercised, or we issue additional shares of common stock in the future, there will be further dilution to the investors participating in this
offering. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom32534_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risk factors described below and the risk
factors incorporated by reference to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the period ended December&nbsp;31, 2019, our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended
September&nbsp;30, 2020, and any subsequent Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form
<FONT STYLE="white-space:nowrap">8-K</FONT> we file after the date of this prospectus supplement, and all other information contained or incorporated by reference into this prospectus supplement and the accompanying prospectus, including our
financial statements and the related notes, as updated by our subsequent filings under the Exchange Act and in any free writing prospectus that we have authorized for use in connection with this offering before acquiring any of our common stock.
These risks could have a material and adverse impact on our business, results of operations, financial condition and growth prospects, which may cause the trading price of our common stock to decline and you could lose all or part of your
investment. The risks discussed below also include forward-looking statements and our actual results may differ substantially from those discussed in these forward-looking statements. See &#147;Cautionary Note Regarding Forward-Looking
Statements.&#148; </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to This Offering and Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The price of our common stock historically has been volatile, which may affect the price at which you could sell any shares of our common stock.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price for our common stock historically has been highly volatile and could continue to be subject to wide fluctuations
in response to various factors. The daily closing market price for our common stock has varied between a high price of $21.40 on September&nbsp;18, 2020 and a low price of $6.12 on March&nbsp;18, 2020 in the twelve-month period ending on
November&nbsp;30, 2020. This volatility may affect the price at which you could sell the shares of our common stock, and the sale of substantial amounts of our common stock could adversely affect the price of our common stock. Our stock price is
likely to continue to be volatile and subject to significant price and volume fluctuations in response to market and other factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the success of competing products or technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results of preclinical studies or clinical trials of our product candidates or those of our competitors;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments or disputes concerning patent applications, issued patents or other proprietary rights;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">results from, and any delays in, research and development efforts, planned clinical trials for our product
candidates, or any other future product candidates, including potential delays due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, and the results of trials of competitors or those of other companies in our market sector;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulatory or legal developments in the U.S. and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the level of expenses related to any of our product candidates or clinical development programs;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the results of our efforts to discover, develop, acquire or <FONT STYLE="white-space:nowrap">in-license</FONT>
additional product candidates or products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by
securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">variations in our financial results or the financial results of companies that are perceived to be similar to us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sales of a substantial number of shares of our common stock in the public market, or the perception in the market
that the holders of a large number of shares intend to sell shares; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">market conditions in the pharmaceutical and biotechnology sectors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">general economic, industry and market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the other factors described in this &#147;Risk Factors&#148; section. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, companies trading in the stock market in general, and the Nasdaq Global Market in particular, have experienced extreme price and
volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating
performance. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of
management&#146;s attention and resources, which could materially and adversely affect our business, financial condition, results of operations and growth prospects. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the net proceeds from this offering and may invest or spend the proceeds in ways with which you do not agree and
in ways that may not yield a return on your investment. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although we currently intend to use the net proceeds from this offering in
the manner described in the section titled &#147;Use of Proceeds&#148; in this prospectus supplement, our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do
not improve our results of operations or enhance the value of our common stock. You will not have the opportunity to influence our decisions on how to use the net proceeds from this offering. The failure by our management to apply these funds
effectively could result in financial losses that could harm our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest the net proceeds from this offering in a
manner that does not produce income or that loses value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>You may experience immediate and substantial dilution. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering price per share in this offering may exceed the net tangible book value per share of our common stock outstanding prior at the
time of sale. Assuming that an aggregate of 4,055,150 shares of our common stock are sold at a price of $12.33 per share (the last reported sale price of our common stock on the Nasdaq Global Market on November&nbsp;30, 2020) for aggregate net
proceeds of $48.3&nbsp;million, after deducting commissions and estimated offering expenses payable by us, investors in this offering would experience immediate dilution of $6.24 per share, representing the difference between our as adjusted net
tangible book value per share as of September&nbsp;30, 2020, after giving effect to this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we have a significant
number of stock options outstanding. The exercise of any of these outstanding options could result in further dilution. Further, because we expect we will need to raise additional capital to fund our future activities, we may in the future sell
substantial amounts of common stock or securities convertible into or exchangeable for common stock. Future issuances of common stock or common stock-related securities, together with the exercise of outstanding stock options, if any, may result in
further dilution. For additional information on the dilution that you may experience immediately after this offering, see the section titled &#147;Dilution.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in
additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional capital
will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other
equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain
rights superior to our existing stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, sales of a substantial number of shares of our outstanding common stock in the
public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. Significant portions of these
shares are held by a relatively small number of stockholders. Sales by our stockholders of a substantial number of shares, or the expectation that such sales may occur, could significantly reduce the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject
to stockholder approval. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&nbsp;30, 2020, our executive officers, directors, five percent or greater stockholders and
their affiliates beneficially own approximately 46.0% of our outstanding voting stock. These stockholders will have the ability to influence us through their ownership positions. These stockholders may be able to determine all matters requiring
stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited
acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Sales of a
substantial number of shares of our common stock in the public market could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial
number of shares of our common stock in the public market or the perception that these sales might occur could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity
securities. We are unable to predict the effect that such sales may have on the prevailing market price of our common stock. In addition, the sale of substantial amounts of our common stock could adversely impact its price. As of November&nbsp;30,
2020, we had outstanding 19,629,219 shares of our common stock and options to purchase 3,694,147 shares of our common stock. The sale or the availability for sale of a large number of shares of our common stock in the public market could cause the
price of our common stock to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The actual number of shares we will issue under the sales agreement, at any one time or in total, is
uncertain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to certain limitations in the sales agreement and compliance with applicable law, we have the discretion to
deliver a placement notice to the Agents at any time throughout the term of the sales agreement. The number of shares that are sold by the Agents after delivering a placement notice will fluctuate based on the market price of our common stock during
the sales period and limits we set with the agents. Because the price per share of each share sold will fluctuate based on the market price of our common stock during the sales period, it is not possible at this stage to predict the number of shares
that will be ultimately issued. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The common stock offered hereby will be sold in &#147;at the market offerings,&#148; and investors who buy shares
at different times will likely pay different prices. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investors who purchase shares in this offering at different times will likely
pay different prices, and so may experience different outcomes in their investment results. We will have discretion, subject to market demand, to vary the timing, prices, and numbers of shares sold. There is no minimum or maximum sales price in this
offering. Investors may experience a decline in the value of their shares as a result of share sales made at prices lower than the prices they paid. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research, or publish inaccurate or unfavorable
research, about our business, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our common stock will
depend, in part, on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts may not publish an adequate amount of research on us, which may negatively impact the trading price
for our stock. In addition, if one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. Further, if our operating results fail to meet the
forecasts of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume
to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any,
will be your sole source of gain. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We currently intend to
retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common
stock will be your sole source of gain for the foreseeable future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148; as defined in the JOBS Act and a
&#147;smaller reporting company&#148; as defined in the Exchange Act and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies, which could make our common stock
less attractive to investors and adversely affect the market price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For so long as we remain an &#147;emerging growth
company&#148; as defined in the JOBS Act, we may take advantage of certain exemptions from various requirements applicable to public companies that are not &#147;emerging growth companies&#148; including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions of Section&nbsp;404(b) of the Sarbanes-Oxley Act requiring that our independent registered public
accounting firm provide an attestation report on the effectiveness of our internal control over financial reporting; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the &#147;say on pay&#148; provisions (requiring a <FONT STYLE="white-space:nowrap">non-binding</FONT>
shareholder vote to approve compensation of certain executive officers) and the &#147;say on golden parachute&#148; provisions (requiring a <FONT STYLE="white-space:nowrap">non-binding</FONT> shareholder vote to approve golden parachute arrangements
for certain executive officers in connection with mergers and certain other business combinations) of the Dodd-Frank Act and some of the disclosure requirements of the Dodd-Frank Act relating to compensation of our executive officers; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the requirement to provide detailed compensation discussion and analysis in proxy statements and reports filed
under the Exchange Act and instead provide a reduced level of disclosure concerning executive compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of
these reporting exemptions until we are no longer an emerging growth company, which in certain circumstances could be for up to five years. We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year
(a)&nbsp;following the fifth anniversary of the completion of the IPO (b)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion or (c)&nbsp;in which we are deemed to be a large accelerated filer, which requires the market
value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> to exceed $700.0&nbsp;million as of the prior June&nbsp;30th, and (2)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock
less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company&#148; as defined in the Exchange Act. We may continue to be a
smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that our voting
and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is more than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual
revenues were more than $100.0&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> was more
than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. Although we are still evaluating the JOBS Act, we currently intend to take advantage of some, but not all, of the reduced regulatory and reporting requirements
that will be available to us so long as we qualify as an &#147;emerging growth company&#148; and &#147;smaller reporting company.&#148; We have elected to avail ourselves of this exemption and, therefore, we are not subject to the same new or
revised accounting standards as other public companies that are not emerging growth companies or smaller reporting companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new
guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations. In addition, our independent registered public accounting firm will not be required to provide
an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an &#147;emerging growth company,&#148; which may increase the risk that material weaknesses or significant deficiencies in our
internal control over financial reporting go undetected. Likewise, so long as we qualify as a &#147;smaller reporting company&#148; or an &#147;emerging growth company,&#148; we may elect not to provide you with certain information, including
certain financial information and certain information regarding compensation of our executive officers, that we would otherwise have been required to provide in filings we make with the SEC, which may make it more difficult for investors and
securities analysts to evaluate our company. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less
active trading market for our common stock, and our stock price may be more volatile and may decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The market price of our common stock may be
adversely affected by market conditions affecting the stock markets in general, including price and trading fluctuations on the Nasdaq Global Market. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market conditions may result in volatility in the level of, and fluctuations in, market prices of stocks generally and, in turn, our common
stock and sales of substantial amounts of our common stock in the market, in each case being unrelated or disproportionate to changes in our operating performance. Concerns over global stability and economic conditions in the U.S. and abroad have
contributed to the extreme volatility of the markets, which may have an effect on the market price of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our ability to utilize our
net operating loss, or NOL, carryforwards and certain other tax attributes may be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to utilize our NOL
carryforwards to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income before the expiration dates of the NOL carryforwards, and we cannot predict with
certainty when, or whether, we will generate sufficient taxable income to use all of our NOL carryforwards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Sections 382 and 383 of
the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#147;ownership change,&#148; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a
three-year period, the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes (such as research and development tax
credits) to offset its post-change income or taxes may be limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience ownership changes in the future (some of which may
be outside our control), including as a result of this offering. As a result, if we earn net taxable income, our ability to use our <FONT STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards and other tax attributes to offset U.S. federal
taxable income may be subject to limitations under </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sections 382 and 383 of the Code, which could potentially result in increased future tax liability to us. In addition, at the state level, our NOL carryforwards may also be impaired or limited,
which could increase the amount of state taxes owed in future taxable periods. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>U.S. federal income tax reform could adversely affect our business
and financial condition. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules dealing with U.S. federal, state, and local income taxation are constantly under review through
the legislative process and by the Internal Revenue Service and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many such
changes have been made and changes are likely to continue to occur in the future. For example, the Tax Cuts and Jobs Act, or the TCJA, was enacted in 2017 and significantly reformed the Internal Revenue Code of 1986, as amended. The TCJA, among
other things, contains significant changes to corporate and individual taxation, some of which could adversely impact an investment in our common stock. Additionally, on March&nbsp;27, 2020, President Trump signed into law the Coronavirus Aid,
Relief and Economic Security Act, which included certain changes in tax law intended to stimulate the U.S. economy in light of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak, including temporary beneficial changes to the treatment of
NOLs, interest deductibility limitations and payroll tax matters. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal
and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax authorities may disagree
with our positions and conclusions regarding certain tax positions, resulting in unanticipated costs, taxes or <FONT STYLE="white-space:nowrap">non-realization</FONT> of expected benefits. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A tax authority may disagree with tax positions that we have taken, which could result in increased tax liabilities. For example, a tax
authority could challenge our allocation of income by tax jurisdiction and the amounts paid between our affiliated companies pursuant to our intercompany arrangements and transfer pricing policies, including amounts paid with respect to transfers of
intellectual property and our intellectual property development. Such an assertion, if successful, could increase our expected tax liability in one or more jurisdictions. A tax authority may take the position that material income tax liabilities,
interest and penalties are payable by us, in which case, we expect that we might contest such assessment. Contesting such an assessment may be lengthy and costly and if we were unsuccessful in disputing the assessment, the implications could
increase our anticipated effective tax rate, where applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom32534_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue and sell shares of our common stock having aggregate sales proceeds of up to $50.0&nbsp;million from time to time. The amount of
proceeds from this offering will depend upon the number of shares of our common stock sold and the market price at which they are sold. There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement as a
source of financing. Therefore, the actual total public offering amount, commissions and proceeds to us, if any, are not determinable at this time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to use any net proceeds from this offering primarily to fund activities relating to the advancement of our product
candidates <FONT STYLE="white-space:nowrap">ADI-001</FONT> and <FONT STYLE="white-space:nowrap">ADI-002,</FONT> our internal discovery research, other pipeline candidates and to fund the continued development of our gamma delta T cell platform,
working capital and capital expenditures and for other general corporate purposes. General corporate purposes may include research and development costs, including the conduct of one or more clinical trials and process development and manufacturing
of our product candidates, potential strategic acquisitions of complementary businesses, services or technologies, expansion of our technology infrastructure and capabilities, working capital and capital expenditures. We may temporarily invest the
net proceeds in a variety of capital preservation instruments, including investment grade, interest bearing instruments and U.S. government securities, until they are used for their stated purpose. We have not determined the amount of net proceeds
to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom32534_6"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid cash dividends on our capital stock. We intend to retain all of our future earnings, if any, to finance the
growth and development of our business. We do not intend to pay cash dividends to our stockholders in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom32534_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the public
offering price per share of our common stock in this offering and the as adjusted net tangible book value per share of our common stock immediately after this offering. Our net tangible book value as of September&nbsp;30, 2020 was approximately
$95.6&nbsp;million, or approximately $4.88 per share of common stock. Net tangible book value per share represents the amount of total tangible assets (total assets less goodwill and <FONT STYLE="white-space:nowrap">in-process</FONT> research and
development) less total tangible liabilities (total liabilities less the contingent consideration liability related to the Contingent Value Right Agreement), divided by the number of shares of our common stock outstanding as of September&nbsp;30,
2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution in net tangible book value per share to new investors participating in this offering represents the difference between the
amount per share paid by purchasers in this offering and the as adjusted net tangible book value per share of our common stock immediately after giving effect to this offering. After giving effect to the assumed sale of 4,055,150 shares of our
common stock in the aggregate amount of approximately $50,000,000 at an assumed offering price of $12.33 per share, the last reported sale price of our common stock on November&nbsp;30, 2020, and after deduction of commissions and estimated
aggregate offering expenses payable by us, our as adjusted net tangible book value as of September&nbsp;30, 2020 would have been approximately $143.9&nbsp;million, or approximately $6.09 per share of common stock. This represents an immediate
increase in net tangible book value of $1.21 per share of common stock to our existing stockholders and an immediate dilution in net tangible book value of $6.24 per share of common stock to investors participating in this offering at the assumed
offering price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors is determined by subtracting as adjusted net tangible book value per share after this
offering from the assumed public offering price per share paid by new investors. The following table illustrates this per share dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assumed offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share as of September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to new investors attributable to this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjusted net tangible book value per share as of September&nbsp;30, 2020, after giving effect to
this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 6.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution in net tangible book value per share to new investors participating in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The table above assumes for illustrative purposes that an aggregate of 4,055,150 shares of our common stock
are sold at a price of $12.33 per share, the last reported sale price of our common stock on The Nasdaq Global Market on November&nbsp;30, 2020, for aggregate gross proceeds of approximately $50,000,000. The shares sold in this offering, if any,
will be sold from time to time at various prices. An increase of $1.00 per share in the price at which the shares are sold from the assumed offering price of $12.33 per share shown in the table above, assuming all of our common stock in the
aggregate amount of approximately $50,000,000 is sold at that price, would result in an increase to our adjusted net tangible book value per share after the offering to $1.29 and an increase in the dilution in net tangible book value per share to
new investors in this offering to $7.16 after deducting commissions payable by us. A decrease of $1.00 per share in the price at which the shares are sold from the assumed offering price of $12.33 per share shown in the table above, assuming all of
our common stock in the aggregate amount of approximately $50,000,000 is sold at that price, would result in a decrease to our adjusted net tangible book value per share after the offering to $1.12 and a decrease in the dilution in net tangible book
value per share to new investors in this offering to $5.33, after deducting commissions payable by us. This information is supplied for illustrative purposes only, and will adjust based on the actual offering prices, the actual number of shares that
we offer and sell in this offering and other terms of each sale of shares in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information above and in the foregoing table is based upon 19,589,637 shares of our common stock
outstanding as of September&nbsp;30, 2020. This information above and in the foregoing table excludes as of September&nbsp;30, 2020: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">3,269,399 shares of common stock issuable upon the exercise of stock options outstanding as of September&nbsp;30,
2020 at a weighted-average exercise price of $10.49 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">226,191 shares of common stock issuable upon the exercise of stock warrants outstanding as of September&nbsp;30,
2020 at an exercise price of $11.32 per share; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">1,462,006 shares of common stock reserved for future issuance under our 2018 Plan as of September&nbsp;30, 2020;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">636,168 shares of common stock for the future issuance under our 2015 Plan as of September&nbsp;30, 2020;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">131,432 shares of common stock reserved for the future issuance under our 2018 ESPP as of September&nbsp;30,
2020; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">472,473 shares of common stock issuable upon the exercise of stock options issued under the 2015 Plan, 2018 Plan
and as inducement grants after September&nbsp;30, 2020 at an exercise price of $12.14 per share. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may
choose to raise additional capital in the future through the sale of equity or convertible debt securities due to market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.
To the extent that any of our outstanding options are exercised; new options are issued under our equity incentive plans; or we issue additional shares of common stock or other equity or convertible debt securities in the future, there will be
further dilution to investors participating in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom32534_8"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following discussion is a summary of the material U.S. federal income tax
considerations for <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering. For purposes of this discussion, a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial owner of our common stock that is for U.S. federal income tax purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign corporation or any other foreign organization taxable as a corporation for U.S. federal income tax
purposes; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a foreign estate or trust, the income of which is not subject to U.S. federal income tax on a net income basis.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not address the tax treatment of partnerships or other entities or arrangements that are treated
as partnerships or other pass-through entities for U.S. federal income tax purposes or persons that hold their common stock through partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold
our common stock should consult his, her or its tax advisor regarding the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, or the Code, existing and proposed U.S.
Treasury regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus supplement and all of which are subject to change or to differing interpretation, possibly with
retroactive effect. Any such change or differing interpretation could alter the tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus supplement. There can be no assurance that the Internal Revenue
Service, or the IRS, will not challenge one or more of the tax consequences described herein. We assume in this discussion that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds shares of our common stock as a capital asset within the
meaning of Section&nbsp;1221 of the Code, which is generally property held for investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion does not address all aspects
of U.S. federal income taxation that may be relevant to a particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances nor does it address
any U.S. state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consideration, the alternative minimum tax, the rules regarding qualified small business stock within the meaning of Section&nbsp;1202 of the Code, the Medicare tax on net
investment income or any other aspect of any U.S. federal tax other than income taxes. This discussion also does not consider any specific facts or circumstances that may apply to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and does
not address the special tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations
that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(I)(2) of the Code and entities all of
the interests of which are held by qualified foreign pension funds; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that have a functional currency other than the U.S. dollar; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or
other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to our
common stock being taken into account in an applicable financial statement; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise
as compensation; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discussion is for general information only and is not tax advice. Accordingly, all prospective
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders of our common stock should consult their tax advisors with respect to the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the purchase,
ownership and disposition of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions on Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in the &#147;Dividend Policy&#148; section above, we do not anticipate paying any cash dividends on our capital stock in the
foreseeable future. Distributions, if any, on our common stock will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax
principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a <FONT STYLE="white-space:nowrap">tax-free</FONT> return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s
investment, up to such holder&#146;s tax basis in the common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below in &#147;Gain on Sale or Other Taxable Disposition of Our Common Stock.&#148; Any
such distributions will also be subject to the discussions below under the sections titled &#147;Backup Withholding and Information Reporting&#148; and &#147;FATCA.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the discussion in the following two paragraphs in this section, dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
generally will be subject to withholding of U.S. federal income tax at a 30% rate or such reduced rate specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. Dividends that are treated as
effectively connected with a trade or business conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or
a fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States, are generally exempt from the 30% withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder satisfies applicable
certification and disclosure requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal income tax rates applicable to United States persons (as defined in the
Code). Any U.S. effectively connected income received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30% rate
or such reduced rate specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock who claims the benefit of an applicable income tax treaty
between the United States and such holder&#146;s country of residence generally will be required to provide a properly executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or successor form) to the applicable withholding agent and satisfy applicable certification and other requirements. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to consult
their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is eligible for a reduced rate of U.S. withholding tax under an income tax treaty may
obtain a refund or credit of any excess amounts withheld by timely filing a U.S. tax return with the IRS. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Gain on Sale or Other Taxable Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the discussions below under &#147;Backup Withholding and Information Reporting&#148; and &#147;FATCA,&#148; a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder will not be subject to any U.S. federal income or withholding tax on any gain realized upon such holder&#146;s sale or other taxable disposition of shares of our common stock unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct
of a U.S. trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed base maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, in which
case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on a net income basis at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax described above in &#147;Distributions on Our Common Stock&#148; also may apply; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in
the United States for 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30% tax (or such lower rate as may be
specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital losses of the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income
tax returns with respect to such losses; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition
(or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a U.S. real property holding corporation, unless our common stock is regularly traded on an established securities market and the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder has held no more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, at any time during the shorter of the <FONT STYLE="white-space:nowrap">5-year</FONT>
period ending on the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. Generally, a corporation is a U.S. real property holding corporation only if the fair market value of
its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or business. Although there can be no assurance, we do not
believe that we are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. No assurance can be provided that our common stock will be regularly traded on an established securities market for
purposes of the rules described above. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the distributions on
our common stock paid to such holder and the tax withheld, if any, with respect to such distributions. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders may have to comply with specific certification procedures to establish that the holder is
not a United States person (as defined in Section&nbsp;7701(a)(30) of the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Dividends paid to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to withholding of U.S. federal income tax, as described above in &#147;Distributions on Our Common Stock,&#148; generally will be exempt from U.S. backup withholding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Information reporting and backup withholding will generally apply to the proceeds of a disposition of our common stock by a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and satisfies certain other
requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder where the transaction is
effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes, dispositions effected through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of
a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of the information
reporting and backup withholding rules to them. Copies of information returns may be made available to the tax authorities </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated under the provisions of a specific treaty or agreement. Backup withholding is not an
additional tax. Any amounts withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder can be refunded or credited against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holder&#146;s U.S. federal income tax liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FATCA </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Foreign Account Tax Compliance Act, or FATCA, generally imposes a U.S. federal withholding tax at a rate of 30% on payments of dividends
on, or subject to the discussion of certain proposed U.S. Treasury regulations below, gross proceeds from the sale or other disposition of, our common stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial
institution,&#148; such foreign entity undertakes certain due diligence, reporting, withholding, and certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; such foreign entity identifies
certain of its U.S. investors, if any, or (iii)&nbsp;the foreign entity is otherwise exempt under FATCA. However, proposed regulations, if finalized in their present form, would eliminate the federal withholding tax of 30% of the gross proceeds of a
sale or other disposition of our common stock. Taxpayers (including withholding agents) may generally rely on the proposed regulations until final regulations are issued. Under certain circumstances, a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be eligible for refunds or credits of this withholding tax. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described
in this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the possible implications of this legislation on their investment in our common stock and the entities through which they hold
our common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of the 30% withholding tax under FATCA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The preceding discussion of U.S. federal income tax considerations is for general information only. It is not tax advice. Each prospective investor should
consult its tax advisor regarding the particular U.S. federal, state and local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of purchasing, holding and disposing of our common stock, including the consequences of any proposed
change in applicable laws. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom32534_9"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following description of our common stock and preferred stock summarizes the material terms and provisions of the common stock that we
may offer under this prospectus supplement. The following description of our capital stock does not purport to be complete and is subject to, and qualified in its entirety by, our amended and restated certificate of incorporation and restated bylaws
and by applicable law. The terms of our common stock and preferred stock may also be affected by Delaware law. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorized Capital Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 150,000,000 shares of common stock, par value $0.0001 per share, and 10,000,000 shares of preferred
stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of November&nbsp;30, 2020, 19,629,219
shares of our common stock were outstanding and held by 58 stockholders of record. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The
holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any
preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets
remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. All outstanding shares are fully paid and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we issue shares of common stock under this prospectus supplement, the shares will fully be paid and nonassessable and will not have, or
be subject to, any preemptive or similar rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Undesignated Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is authorized to issue up to 10,000,000 shares of undesignated preferred stock in one or more series without stockholder
approval. Our board of directors may determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.
The purpose of authorizing our board of directors to issue preferred stock in one or more series and determine the number of shares in the series and its rights and preferences is to eliminate delays associated with a stockholder vote on specific
issuances. Examples of rights and preferences that the board of directors may fix are: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">dividend rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conversion rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">terms of redemption; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">liquidation preference; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">sinking fund terms; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares constituting, or the designation of, such series, any or all of which may be greater than
the rights of common stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of authorized but unissued shares of undesignated preferred stock may enable
our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a
takeover proposal is not in the best interests of us or our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute
the voting or other rights of the proposed acquirer, stockholder or stockholder group. The rights of holders of our common stock described above, will be subject to, and may be adversely affected by, the rights of any preferred stock that we may
designate and issue in the future. The issuance of shares of undesignated preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the
rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the
terms of our investors&#146; rights agreement entered into in November 2017 (the &#147;Investors&#146; Rights Agreement&#148;), certain of our stockholders are entitled to rights with respect to the registration of their shares under the Securities
Act until the earliest of (a)&nbsp;January 2023, (b) the date on which such holder ceases to hold registrable securities, or (c)&nbsp;such holder&#146;s registrable securities could be sold without any restriction on volume or manner of sale on any
three-month period under Rule 144 or any successor rule, as described below. We refer to these shares collectively as registrable securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Demand
Registration Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain holders of our common stock are entitled to demand registration rights. Under the terms of the
Investors&#146; Rights Agreement, we will be required, upon the written request of the holders of at least 20% of our outstanding registrable securities, as defined in the Investors&#146; Rights Agreement, to file a registration statement with
respect to at least 40% of the registrable securities and use commercially reasonable efforts to effect the registration of all or a portion of their registrable securities for public resale so long as the total amount of registrable shares
requested to be registered has an anticipated aggregate offering price to the public, net of selling expenses, of at least $15.0&nbsp;million. We are required to effect only two registrations pursuant to this provision of the Investors&#146; Rights
Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Short-Form Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of at least 10% of our outstanding registrable securities can request that we register all or part of their shares on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> if we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and if the aggregate offering price, net of selling expenses, is at least $10.0&nbsp;million. We are
required to effect only two registrations in any twelve month period pursuant to the Investors&#146; Rights Agreement. The right to have such shares registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> is further subject to other specified
conditions and limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Piggyback Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the investors&#146; rights agreement, if we register any of our securities either for our own account or for the account of other
security holders, the holders of these shares are entitled to include their shares in the registration. Subject to certain exceptions contained in the Investors&#146; Rights Agreement, we and the underwriters may limit the number of shares included
in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion will not jeopardize the success of the offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Investors&#146; Rights Agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of
registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom32534_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;1, 2020, we entered into a sales agreement with the Agents under which we may issue and sell shares of our common stock
having an aggregate gross sales price of up to $50,000,000 from time to time through the Agents, acting as agents. The sales agreement has been filed as an exhibit to our registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> of
which this prospectus supplement forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon delivery of a placement notice and subject to the terms and conditions of the sales
agreement, the Agents may sell our common stock by any method permitted by law deemed to be an &#147;at the market offering&#148; as defined in Rule 415(a)(4) promulgated under the Securities Act. We may instruct the Agents not to sell common stock
if the sales cannot be effected at or above the price designated by us from time to time. We or the Agents may suspend the offering of common stock upon notice and subject to other conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay the Agents commissions, in cash, for their services in acting as agent in the sale of our common stock. The Agents will be
entitled to compensation at a fixed commission rate of 3.0% of the gross proceeds from each sale of our common stock. Because there is no minimum offering amount required as a condition to close this offering, the actual total public offering
amount, commissions and proceeds to us, if any, are not determinable at this time. We have also agreed to reimburse the Agents for certain specified expenses, including the fees and disbursements of their legal counsel in an amount not to exceed
$50,000, as well as ongoing disbursements of their legal counsel payable in the amount of up to $15,000 in connection with each diligence bring-down thereafter. We estimate that the total expenses for the offering, excluding compensation and
reimbursements payable to the Agents under the terms of the sales agreement, will be approximately $175,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Settlement for sales of
common stock will occur on the second business day following the date on which any sales are made, or on some other date that is agreed upon by us and the Agents in connection with a particular transaction, in return for payment of the net proceeds
to us. Sales of our common stock as contemplated in this prospectus supplement will be settled through the facilities of The Depository Trust Company or by such other means as we and the Agents may agree upon. There is no arrangement for funds to be
received in an escrow, trust or similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Agent will use its commercially reasonable efforts, consistent with its sales
and trading practices, to solicit offers to purchase the common stock shares under the terms and subject to the conditions set forth in the sales agreement. In connection with the sale of the common stock on our behalf, each Agent will be deemed to
be an &#147;underwriter&#148; within the meaning of the Securities Act and the compensation of each Agent will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to the Agents against
certain civil liabilities, including liabilities under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering of our common stock pursuant to the sales
agreement will terminate upon the termination of the sales agreement as permitted therein. We and each Agent (with respect to itself) may each terminate the sales agreement at any time upon two days&#146; prior notice or by an Agent at any time in
certain circumstances, including the occurrence of a material and adverse change in our business or financial condition that makes it impractical or inadvisable to market our common stock or to enforce contracts for the sale of our common stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Agents and their respective affiliates may in the future provide various investment banking, commercial banking and other financial
services for us and our affiliates, for which services they may in the future receive customary fees. To the extent required by Regulation M, the Agents will not engage in any market making activities involving our common stock while the offering is
ongoing under this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus in electronic format may be made
available on a website maintained by the Agents and the Agents may distribute this prospectus supplement and the accompanying prospectus electronically. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom32534_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal matters relating to the shares of common stock offered hereby will be passed upon for us by Goodwin Procter LLP, Boston,
Massachusetts. Certain legal matters in connection with this offering will be passed upon for the underwriters by Latham&nbsp;&amp; Watkins LLP. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom32534_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of resTORbio, Inc. as of December&nbsp;31, 2019 and 2018, and for each of the years in the three-year
period ended December&nbsp;31, 2019, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the
authority of said firm as experts in accounting and auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audited historical financial statements of Adicet Bio, Inc. included in
Exhibit 99.5 of Adicet Bio, Inc.&#146;s Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> dated September&nbsp;16, 2020 have been so incorporated in reliance on the report (which contains an explanatory paragraph relating to Adicet
Bio, Inc.&#146;s ability to continue as a going concern as described in Note 1 to the financial statements) of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing
and accounting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom32534_13"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act with respect
to the shares of common stock offered by this prospectus supplement. This prospectus supplement does not contain all the information set forth in the registration statement and its exhibits and schedules, portions of which have been omitted as
permitted by the rules and regulations of the SEC. You should read the registration statement and its exhibits and schedules carefully for provisions that may be important to you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. The SEC also maintains a website at
www.sec.gov that contains periodic and current reports, proxy and information statements, and other information regarding registrants that are filed electronically with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These documents are also available, free of charge, through the Investors section of our website, which is located at www.adicetbio.com.
Information contained on our website is not incorporated by reference into this prospectus supplement or the accompanying prospectus and you should not consider information on our website to be part of this prospectus supplement or the accompanying
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the authority to designate and issue more than one class or series of stock having various preferences, conversion
and other rights, voting powers, restrictions, limitations as to dividends, qualifications, and terms and conditions of redemption. See &#147;Description of Capital Stock. We will furnish a full statement of the relative rights and preferences of
each class or series of our stock which has been so designated and any restrictions on the ownership or transfer of our stock to any shareholder upon request and without charge. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom32534_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference the information and reports we file with it into our registration statement of which this
prospectus supplement is a part, which means that we can disclose important information to you by referring you to these documents. The information incorporated by reference is an important part of this prospectus supplement, and information that we
file later with the SEC will automatically update and supersede the information already incorporated by reference. Any statement contained in a previously </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus
supplement modifies or replaces that statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We incorporate by reference our documents listed below and any future filings made by us
with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, between the date of this prospectus supplement and the termination of the offering of the securities described in this prospectus supplement. We are not, however,
incorporating by reference any documents or portions thereof, whether specifically listed below or filed in the future, that are not deemed &#147;filed&#148; with the SEC, including any information furnished pursuant to Items 2.02 or 7.01 of Form <FONT
STYLE="white-space:nowrap">8-K</FONT> or related exhibits furnished pursuant to Item 9.01 of Form <FONT STYLE="white-space:nowrap">8-K:</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000156459020010474/torc-10k_20191231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2019, filed with the SEC on March&nbsp;12, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information specifically incorporated by reference into our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000156459020010474/torc-10k_20191231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2019 from our definitive proxy statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000156459020013384/torc-def14a_20200506.htm">Schedule 14A</A>
(other than information furnished rather than filed), filed with the SEC on March&nbsp;27, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2020, June&nbsp;30, 2020 and September&nbsp;
30, 2020, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000156459020022817/torc-10q_20200331.htm">May 7, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1720580/000156459020034835/torc-10q_20200630.htm">July&nbsp;30,
 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1720580/000156459020051476/acet-10q_20200930.htm">November<U></U>&nbsp;5, 2020</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or Form
<FONT STYLE="white-space:nowrap">8-K/A</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312520041370/d881209d8k.htm">February&nbsp;
19, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312520097142/d884625d8k.htm">April&nbsp;3, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312520124620/d894305d8k.htm">April<U></U>&nbsp;29,
2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312520127654/d925728d8k.htm">April&nbsp;30, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000156459020027123/torc-8k_20200528.htm">May<U></U>&nbsp;28,
2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312520158296/d904354d8k.htm">June<U></U>&nbsp;2, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000156459020028441/torc-8k_20200603.htm">June&nbsp;5,
2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312520176314/d920890d8k.htm">June&nbsp;23, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312520188831/d220319d8k.htm">July<U></U>&nbsp;
7, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312520200676/d92144d8k.htm">July&nbsp;
28, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1720580/000119312520245865/d50689d8k.htm">September&nbsp;
15, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1720580/000119312520246853/d24517d8k.htm">September&nbsp;
16, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1720580/000119312520249151/d91031d8k.htm">September&nbsp;
18, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1720580/000119312520259936/d48006d8k.htm">September&nbsp;
30, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1720580/000119312520261344/d38272d8ka.htm">October&nbsp;
1, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1720580/000119312520266358/d137275d8k.htm">October&nbsp;
8, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1720580/000119312520274012/d80020d8k.htm">October&nbsp;
22, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1720580/000119312520276994/d71827d8k.htm">October&nbsp;
26, 2020</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1720580/000119312520306229/d69549d8k.htm">December&nbsp;
1, 2020</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1720580/000119312520307368/d17010d8k.htm">December&nbsp;1, 2020</A> (in each case, except for information contained therein which is furnished
rather than filed); and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312518015584/d528214d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on January&nbsp;22, 2018 (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-28259)</FONT> under Section&nbsp;12(b) of the Exchange Act, including any amendments or reports filed
for the purpose of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a copy of these filings, and any exhibits we have
specifically incorporated by reference as an exhibit in this prospectus supplement, at no cost by writing us at the following address: Investor Relations Department, Adicet Bio, Inc., 500 Boylston Street, 13th Floor, Boston, MA 02116, telephone
(857) <FONT STYLE="white-space:nowrap">315-5528.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may also access these documents, free of charge on the SEC&#146;s website at
www.sec.gov or on our website at www.adicetbio.com. The information contained on, or that can be accessed through, our website does not constitute part of this prospectus supplement, and the reference to our website address is included in this
prospectus supplement as an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g32534g23a75.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$175,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>12,445,646 Shares of Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Offered by Selling Stockholders </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may from time to time issue,
in one or more series or classes, up to $175,000,000 in aggregate principal amount of our common stock, preferred stock, debt securities, warrants and/or units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, selling stockholders named in this prospectus may from time to time offer and sell up to an aggregate of 12,445,646 shares of our common stock in
one or more offerings, subject to market conditions and prices, liquidity objectives and other investment considerations. We will not receive any of the proceeds from the sale of our common stock by the selling stockholders. We have borne and will
continue to bear the costs relating to registration of these shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer these securities separately or together in units. Each time we sell
securities described herein, and in certain cases where one or more selling stockholders sell securities pursuant to this prospectus, we or the selling stockholders, as applicable, will provide prospective investors with a supplement to this
prospectus that will specify the terms of the securities being offered. We may sell these securities to or through underwriters and also to other purchasers or through agents. We will set forth the names of any underwriters or agents, and any fees,
conversions, or discount arrangements, in the accompanying prospectus supplement. We may not sell any securities under this prospectus without delivery of the applicable prospectus supplement. You should read this document and any prospectus
supplement or amendment carefully before you invest in our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on The Nasdaq Global Select Market under the symbol
&#147;TORC.&#148; On January&nbsp;31, 2019, the closing price for our common stock, as reported on The Nasdaq Global Select Market, was $8.88 per share. Our principal executive offices are located at 500 Boylston Street, 12<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston, Massachusetts 02116. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities
involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading &#147;<A HREF="#toc32534_2">Risk Factors</A>&#148; contained in this prospectus beginning on page 2 and any applicable prospectus
supplement, and under similar headings in the other documents that are incorporated by reference into this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this Prospectus is&nbsp;February 12, 2019 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_3">Cautionary Statement Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_4">The Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_6">Securities We May Offer or That a Selling Stockholder May
Offer</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_7">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_8">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_9">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_10">Description of Units</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_11">Selling Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_12">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_13">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_14">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_15">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc32534_16">Incorporation by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a
&#147;shelf&#148; registration process. Under this shelf registration process, we may from time to time sell any combination of the securities described in this prospectus in one or more offerings for an aggregate initial offering price of up to
$175,000,000. In addition, the selling stockholders may from time to time sell up to an aggregate amount of 12,445,646, shares of our common stock in one or more offerings, subject to market conditions and prices, liquidity objectives and other
investment considerations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities we or the selling stockholders may
offer. Each time we sell securities described herein, and in certain cases where one or more selling stockholders sell securities pursuant to this prospectus, we or the selling stockholders, as applicable, will provide one or more prospectus
supplements that will contain specific information about the terms of the offering. The prospectus supplement may also add, update or change information contained in this prospectus. You should read both this prospectus and the accompanying
prospectus supplement together with the additional information described under the heading &#147;Where You Can Find More Information&#148; beginning on page <B></B>of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in or incorporated by reference in this prospectus, any accompanying prospectus supplement
or in any related free writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus and the accompanying prospectus supplement do not constitute an offer to sell or the
solicitation of an offer to buy any securities other than the securities described in the accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or
solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their respective dates.
Our business, financial condition, results of operations and prospects may have changed materially since those dates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context
otherwise indicates, references in this prospectus to &#147;resTORbio&#148;, &#147;we&#148;, &#147;our&#148;, &#147;us&#148; and &#147;the Company&#148; refer, collectively, to resTORbio, Inc. and, where appropriate, our subsidiary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. You should carefully consider the risks referenced below and described in the
documents incorporated by reference in this prospectus and any applicable prospectus supplement, as well as other information we include or incorporate by reference into this prospectus and any applicable prospectus supplement, before making an
investment decision. Our business, financial condition or results of operations could be materially adversely affected by the materialization of any of these risks. The trading price of our securities could decline due to the materialization of any
of these risks, and you may lose all or part of your investment. This prospectus and the documents incorporated herein by reference also contain forward-looking statements that involve risks and uncertainties. Actual results could differ materially
from those anticipated in these forward-looking statements as a result of certain factors, including the risks described below and in the documents incorporated herein by reference, including (i)&nbsp;our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017, as amended, which is on file with the SEC and is incorporated herein by reference, (ii)&nbsp;our Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31, 2018, June&nbsp;30, 2018 and September&nbsp;30, 2018, which are on file with the SEC and are incorporated herein by reference and (iii)&nbsp;other documents we file
with the SEC that are deemed incorporated by reference into this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_3"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of
Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements about our expectations, beliefs, plans, objectives,
assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as &#147;may,&#148; &#147;will,&#148; &#147;could,&#148;
&#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;projects,&#148; &#147;potential,&#148; &#147;continue,&#148; and
similar expressions, or the negative of these terms, or similar expressions. Accordingly, these statements involve estimates, assumptions, risks and uncertainties which could cause actual results to differ materially from those expressed in them.
Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this prospectus, and in particular those factors referenced in the section &#147;Risk Factors.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains forward-looking statements that are based on our management&#146;s belief and assumptions and on information
currently available to our management. These statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity,
performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to,
statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to develop and commercialize RTB101 alone or in combination with rapalogs, such as everolimus or
sirolimus, and other product candidates for the targeted indications and patient populations, including the therapeutic potential and clinical benefits thereof; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ongoing and future clinical trials for RTB101 alone or in combination with rapalogs, such as everolimus or
sirolimus, whether conducted by us or by any future collaborators, including the timing of initiation of these trials and of the anticipated results; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate and degree of market acceptance and clinical utility of any products for which we receive regulatory
approval; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our commercialization, marketing and manufacturing capabilities and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our intellectual property position and strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to identify additional product candidates with significant commercial potential;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to enter into collaborations for the development and commercialization of product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential benefits of any future collaboration; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations related to the use of cash, cash equivalents and marketable securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our
Business Startups Act of 2012, as amended, or the JOBS Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expected uses of the net proceeds from any offering of our securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">developments relating to our competitors and our industry; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government laws and regulations. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference also contain estimates,
projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information
that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.
Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general
publications, government data and similar sources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus and the documents that we incorporate by reference in
this prospectus completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements in this prospectus and the documents we incorporate by reference herein represent
our views as of their respective dates. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current
intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_4"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company developing a new class of innovative medicines that target the biology of aging to prevent
or treat <FONT STYLE="white-space:nowrap">age-related</FONT> diseases with the potential to extend healthy lifespan. Our lead program is selectively targeting the target of rapamycin complex 1, or TORC1, an evolutionarily conserved pathway that
contributes to the decline in function of multiple organ systems. Our lead product candidate, RTB101, is an oral, selective, and potent inhibitor of TORC1. RTB101 inhibits the phosphorylation of multiple targets downstream of TORC1. Inhibition of
TORC1 has been observed to extend lifespan and healthspan in aging preclinical species and to enhance immune, neurologic and cardiac functions, suggesting potential benefits in several aging-related diseases. We licensed the worldwide rights to our
TORC1 program, including RTB101 alone or in combination with rapalogs, such as everolimus, sirolimus, or other mTOR inhibitors, from Novartis International Pharmaceutical Ltd. in March 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decline in immune function that occurs during aging, or immunosenescence, increases susceptibility to a variety of diseases, including
respiratory tract infections, or RTIs, that significantly contribute to morbidity and mortality in the elderly. Our initial focus is on the development of RTB101 as a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunotherapy designed to improve immune function and thereby reduce the incidence of RTIs in the elderly regardless of the causative pathogen. Our TORC1
immunotherapy approach is supported by two randomized, placebo-controlled Phase 2a and Phase 2b clinical trials enrolling more than 900 elderly subjects that provided statistically significant and clinically meaningful results. In 2018, we reported
results from our exploratory dose-ranging randomized, placebo-controlled Phase 2b clinical trial in 652 elderly patients at increased risk of <FONT STYLE="white-space:nowrap">RTI-associated</FONT> morbidity and mortality defined as aged 85 and over,
or <FONT STYLE="white-space:nowrap">65-84</FONT> with one or more of comorbidities including: asthma, chronic obstructive pulmonary disease, or COPD, type 2 diabetes mellitus, or T2DM, or current smoker. The results from this trial demonstrated a
statistically significant and clinically meaningful 30.6% reduction in the percentage of patients with one or more laboratory-confirmed RTIs, the primary endpoint of the trial, in the RTB101 10 mg once daily cohort compared to the placebo cohort.
Prespecified analyses of the patient populations enrolled in the trial demonstrated (i)&nbsp;a statistically significant 52.1% reduction in percentage of patients with severe laboratory-confirmed RTI symptoms in the RTB101 10 mg once daily cohort
compared to the placebo cohort, (ii)&nbsp;a statistically significant 66.7%, 68.9%, and 25.3% reduction in the prespecified endpoint of percentage patients 85 and older, 65 and older with asthma and 65 and older with T2DM, respectively, with one or
more laboratory-confirmed RTIs in the RTB101 10 mg once daily cohort compared to the placebo cohort, and (iii)&nbsp;no reduction in the incidence of laboratory-confirmed RTIs in patients who were current smokers or with COPD in the RTB101 10 mg once
daily cohort compared to the placebo cohort. The lack of efficacy observed in current smokers and patients with COPD is consistent with nonclinical data suggesting that mTOR inhibition exacerbates cigarette smoke-induced lung inflammation in COPD.
The combination of RTB101+everolimus did not meet the primary endpoint suggesting that less TORC1 inhibition with RTB101 10 mg once daily may be more beneficial for reducing the incidence of RTIs in high risk elderly patients. We believe the
collective results from our Phase 2a and Phase 2b clinical trials enrolling more than 900 elderly subjects suggest that RTB101 10 mg once daily may improve the function of the aging immune system and reduce the incidence of laboratory-confirmed RTIs
in elderly patients. In our planned Phase 3 studies, we may enroll elderly subjects 65 and older, excluding current smokers and COPD patients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additional positive results from prespecified analyses for any infection and urinary tract infections, or UTIs, from our Phase 2b trial
demonstrated (i)&nbsp;a statistically significant 23.6% reduction in the percentage of patients with any infection in the RTB101 10 mg once daily cohort compared to the placebo cohort, (ii)&nbsp;a statistically significant 74.6% reduction in the
percentage of patients with one or more UTIs in the RTB101 10 mg twice daily cohort and (iii)&nbsp;a 34.4% reduction in the percentage of patients with one or more UTIs in the RTB101 10 mg once daily cohort. If not otherwise specified, we used a
nominal 5% or lower <FONT STYLE="white-space:nowrap">p-value</FONT> (p &lt; 0.05) to define statistical significance for the clinical trials and data presented in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;31, 2019, one family in this patent portfolio covering compositions of matter has 44 issuances in 33 countries, and is
pending in six. Our issued patents and pending applications with respect to RTB101 are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
expected to expire in 2031 or 2032, depending on eligibility for patent term extension or supplementary protection. Additional pending applications are expected to expire between 2034 and 2037,
exclusive of possible patent term adjustments or extensions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recent scientific findings, including those published in the scientific
journals <I>Cell</I>, <I>Nature</I> and <I>Science</I>, suggest that aging and aging-related conditions, such as immunosenescence, may be attributable not only to random cellular wear and tear, but also to specific intra-cellular signaling pathways,
including the mTOR pathway. mTOR is a protein kinase that signals via two multiprotein complexes, known as TORC1 and TORC2. TORC1 inhibition has been observed to prolong lifespan, improve immune, neurologic, and cardiac function, decrease adiposity,
and delay the onset of aging-related diseases in multiple animal studies. Specifically, with respect to improved immune function, TORC1 inhibition was observed in preclinical and clinical studies to rejuvenate blood, or hematopoietic stem cell
function, increase infection-fighting white blood cell production, enhance rapid and independent of antigen, or innate immunity, and enhance antibody-mediated, or adaptive immunity. On the other hand, TORC2 inhibition has been observed to decrease
lifespan in preclinical studies and cause unwanted side effects of hyperlipidemia and hyperglycemia in certain animals and humans. Therefore, based on these observations and data from more than 900 patients enrolled in the Phase 2a and Phase 2b
clinical trials, we believe our TORC1 program has the potential to improve the function of several aging organ systems such as immune system function and counteract immunosenescence in the elderly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reduced ability of elderly patients to effectively detect and fight infections is most commonly manifested in their susceptibility to RTIs
and the negative effects such infections have on their overall health. RTIs are the second leading cause of hospitalization in people age 85 and over, and the fourth leading cause in people age 65 and over, contributing to high healthcare burdens
and costs for the elderly population and the healthcare system that are three to five times higher than for the younger population. Furthermore, antibiotics, which are ineffective against viruses, are often prescribed indiscriminately to treat RTIs,
which may cause side effects related to antibiotic use and contribute to the growing global problem of antibiotic resistance. As the elderly represent the fastest growing population in the world, we believe there is significant unmet medical need
for innovative therapeutic options for reducing the incidence of RTIs by improving the function of the aging immune system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe
our approach to addressing RTIs in the elderly possesses several clinical and commercial advantages. Our TORC1 program offers an immunotherapy approach that has the potential to address a broad range of viral and bacterial pathogens. Statistically
significant and clinically meaningful reductions in RTI incidence were observed in the Phase 2a and Phase 2b clinical trials with RTB101. We believe the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">risk-to-benefit</FONT></FONT>
ratio of our program observed in clinical studies to date would be well-suited to the elderly due to the following observations: our oral product candidates were well-tolerated in elderly subjects and none of the participants in the active treatment
arms experienced a serious adverse event that was related to the study drug, and the doses being investigated in our Phase 2b clinical trial were 60 to 240 times lower than maximum tolerated doses established in prior clinical trials for other
indications. Based on communications during a high-level policy meeting with the U.S. Food and Drug Administration, we believe a reduction in the incidence of RTIs has the potential to be a clinically relevant endpoint. Based on the results from our
Phase 2b clinical trial with respect to reduction in RTI incidence, we plan to conduct pivotal clinical trials and to seek regulatory approval for commercialization of RTB101 in the United States, Europe and Japan. In some markets, we may
collaborate with third parties for the development and commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management team includes Chen
Schor, our <FONT STYLE="white-space:nowrap">co-founder</FONT> who serves as our President and Chief Executive Officer, and Joan Mannick, M.D., our <FONT STYLE="white-space:nowrap">co-founder</FONT> who serves as our Chief Medical Officer, Meredith
Manning, who serves as our Chief Commercial Officer, and additional veterans in drug development and discovery with executive experience in leading global pharmaceutical companies. Dr.&nbsp;Mannick led the TORC1 clinical program at Novartis
Institutes for Biomedical Research, Inc. prior to our <FONT STYLE="white-space:nowrap">in-licensing</FONT> of the program. We are supported by investors that include both private equity venture capital funds and public healthcare investment funds.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the JOBS Act. As an
emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. We would cease to be an emerging growth company on the date that is the earliest of:
(i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more; (ii)&nbsp;December&nbsp;31, 2023; (iii) the date on which we have issued more than $1&nbsp;billion in nonconvertible debt during the
previous three years; or (iv)&nbsp;the date on which we are deemed to be a large accelerated filer under the rules of the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were
incorporated under the laws of the state of Delaware in July 2016 under the name resTORbio, Inc. Our principal executive offices are located at 500 Boylston Street, 12<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston, MA 02116.
Our telephone number is <FONT STYLE="white-space:nowrap">(857)&nbsp;315-5521,</FONT> and our website is located at www.restorbio.com. No portion of our website is incorporated by reference into this prospectus. We do not incorporate the information
on or accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus. Our common stock trades on The Nasdaq Global Select Market under the
symbol &#147;TORC&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use various trademarks and trade names in our business, including without limitation our corporate name and
logo. All other trademarks or trade names referred to in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and trade names in this prospectus may be referred to without the&nbsp;<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>&nbsp;and &#153; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights
thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of any securities offered under this prospectus for general corporate purposes unless
otherwise indicated in the applicable prospectus supplement. General corporate purposes may include research and development costs, including the conduct of one or more clinical trials and process development and manufacturing of our product
candidates, potential strategic acquisitions of complementary businesses, services or technologies, expansion of our technology infrastructure and capabilities, working capital, capital expenditures and other general corporate purposes. We may
temporarily invest the net proceeds in a variety of capital preservation instruments, including investment grade, interest bearing instruments and U.S. government securities, until they are used for their stated purpose. We have not determined the
amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of net proceeds. We will not receive any proceeds from the sale of shares of our common stock by the selling
stockholders. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_6"></A>SECURITIES WE MAY OFFER OR THAT A SELLING STOCKHOLDER MAY OFFER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains summary descriptions of the securities we may offer from time to time. These summary descriptions are not meant to be
complete descriptions of each security. The particular terms of any security will be described in the applicable prospectus supplement. In addition, the selling stockholders may sell from time to time up to an aggregate of 12,445,646 shares of our
common stock in one or more offerings, subject to market conditions and prices, liquidity objectives and other investment considerations. This prospectus provides you with a general description of the securities we and the selling stockholders may
offer.&nbsp;Each time we sell securities described herein, and in certain cases where one or more selling stockholders sell securities pursuant to this prospectus, we or the selling stockholders, as applicable, will provide prospective investors
with a supplement to this prospectus that will contain specific information about the terms of that offering, including the specific amounts, prices and terms of the securities offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or the selling stockholders may sell the securities to or through underwriters, dealers or agents, directly to purchasers or through a
combination of any of these methods of sale or as otherwise set forth below under &#147;Plan of Distribution.&#148; We and the selling stockholders, as well as any agents acting on our or their behalf, reserve the sole right to accept and to reject
in whole or in part any proposed purchase of securities. Any prospectus supplement will set forth the names of any underwriters, dealers, agents or other entities involved in the sale of securities described in that prospectus supplement and any
applicable fee, commission or discount arrangements with them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_7"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following description of our common stock and preferred stock, together with the additional information we include in any applicable
prospectus supplements, summarizes the material terms and provisions of the common stock and preferred stock that we may offer under this prospectus. The following description of our capital stock does not purport to be complete and is subject to,
and qualified in its entirety by, our certificate of incorporation and bylaws, which are exhibits to the registration statement of which this prospectus forms a part, and by applicable law. The terms of our common stock and preferred stock may also
be affected by Delaware law. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Authorized Capital Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of&nbsp;150,000,000&nbsp;shares of common stock, par value $0.0001 per share,
and&nbsp;10,000,000&nbsp;shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock are undesignated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of January&nbsp;31, 2019, 28,055,344 shares of our common stock were outstanding and held by 7 stockholders of record. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our common
stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any
dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other
subscription rights or redemption or sinking fund provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding up, holders of our
common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. All outstanding shares are fully paid and nonassessable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we issue shares of common stock under this prospectus, the shares will fully be paid and nonassessable and will not have, or be subject
to, any preemptive or similar rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Undesignated Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides for 10,000,000 authorized shares of preferred stock. Our board of directors may determine the rights,
preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. These rights, preferences and privileges could include
dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of
common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. The purpose of authorizing
our board of directors to issue preferred stock in one or more series and determine the number of shares in the series and its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. In addition, the
issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. When we issue shares of preferred stock under this prospectus, the shares will fully be paid and
nonassessable and will not be subject to any preemptive or similar rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The existence of authorized but unissued shares of preferred
stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of
directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or
stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock
could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of
delaying, deterring or preventing a change in control of us. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of our investors&#146; rights agreement entered into in November 2017, certain of our stockholders are entitled to rights
with respect to the registration of their shares under the Securities Act until the earliest of (a)&nbsp;January 2023, (b) the date on which such holder ceases to hold registrable securities, or (c)&nbsp;such holder&#146;s registrable securities
could be sold without any restriction on volume or manner of sale on any three-month period under Rule 144 or any successor rule, as described below. We refer to these shares collectively as registrable securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders
of&nbsp;14,466,883 shares of our common stock, including the 12,445,646 shares of common stock to be registered pursuant to this Registration Statement, are entitled to demand registration rights. Under the terms of the investors&#146; rights
agreement, we will be required, upon the written request of the holders of at least 20% of our outstanding registrable securities, as defined in the investors&#146; rights agreement, to file&nbsp;a registration statement with respect to at least 40%
of the registrable securities and use commercially reasonable efforts to effect the registration of all or a portion of their registrable securities for public resale so long as the total amount of registrable shares requested to be registered has
an anticipated aggregate offering price to the public, net of selling expenses, of at least $15.0&nbsp;million. We are required to effect only two registrations pursuant to this provision of the investors&#146; rights agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Short-Form Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
holders of at least 10% of our outstanding registrable securities can request that we register all or part of their shares on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we are eligible to file&nbsp;a registration statement on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> and if the aggregate offering price, net of selling expenses, is at least $10.0&nbsp;million. We are required to effect only two registrations in any twelve month period pursuant to the investors&#146;
rights agreement. The right to have such shares registered on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> is further subject to other specified conditions and limitations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant
to the investors&#146; rights agreement, if we register any of our securities either for our own account or for the account of other security holders, the holders of these shares are entitled to include their shares in the registration. Subject to
certain exceptions contained in the investors&#146; rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the underwriters determine in our sole discretion
will not jeopardize the success of the offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Indemnification </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our investors&#146; rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of
registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expiration of Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The demand registration rights and short form registration rights granted under the investors&#146; rights agreement will terminate on the
earliest of (a)&nbsp;January 2023, (b) the date on which such holder ceases to hold registrable securities, or (c)&nbsp;such holder&#146;s registrable securities could be sold without any restriction on volume or manner of sale on any three-month
period under Rule 144 or any successor rule, as described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of our Certificate of Incorporation and Bylaws and Delaware Law
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws include a number of provisions that may have the effect of delaying, deferring or
preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue
<FONT STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Board Composition and
Filling Vacancies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides for the division of our board of directors into three classes serving
staggered three-year terms, with one class being elected each year. Our certificate of incorporation also provides that directors may be removed only for cause and then only by the affirmative vote of the holders of
<FONT STYLE="white-space:nowrap">two-thirds</FONT> or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the
size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of
vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Written Consent of
Stockholders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the
stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of
our bylaws or removal of directors by our stockholders without holding a meeting of stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Meetings of Stockholders </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation and bylaws provide that only a majority of the members of our board of directors then in office may call
special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of
stockholders to those matters properly brought before the meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Advance Notice Requirements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as
directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be
taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90&nbsp;days nor more than 120&nbsp;days prior to the first anniversary date of the annual meeting for the preceding year. Our bylaws specify
the requirements as to form and content of all stockholders&#146; notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment to Certificate of Incorporation and Bylaws </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any amendment of our certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our
certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment
of the provisions relating to stockholder action, board composition, limitation of liability and the amendment of our bylaws and certificate of incorporation must be approved by not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the
outstanding shares entitled to vote on the amendment, and not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding shares of each class entitled to vote thereon as a class. Our bylaws may be amended by the affirmative vote
of a majority of the directors then in office, subject to any limitations set forth in the bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled to vote on the amendment, or, if our board of
directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Choice of Forum </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our certificate of
incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for: (1)&nbsp;any derivative action or proceeding brought on our
behalf; (2)&nbsp;any action asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders; (3)&nbsp;any action asserting a claim against us arising pursuant to
any provision of the General Corporation Law of the State of Delaware or our certificate of incorporation or bylaws; or (4)&nbsp;any action asserting a claim governed by the internal affairs doctrine. Our certificate of incorporation also provides
that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the
choice of forum provision contained in our restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;203 of the Delaware General Corporation Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&nbsp;203 of the Delaware General Corporation Law. In general, Section&nbsp;203 prohibits a publicly
held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business
combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and
also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of
directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;203 defines a business combination to include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the
assets of the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock
of the corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the
proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other
financial benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, Section&nbsp;203 defines an interested
stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
common stock is listed on The Nasdaq Global Select Market under the symbol &#147;TORC.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#146;s address is
250 Royall Street, Canton, Massachusetts 02021, and its telephone number is (800) <FONT STYLE="white-space:nowrap">962-4284.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_8"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The paragraphs below describe the general terms and provisions of the debt securities we may issue. When we offer to sell a particular series
of debt securities, we will describe the specific terms of the securities in a supplement to this prospectus, including any additional covenants or changes to existing covenants relating to such series. The prospectus supplement also will indicate
whether the general terms and provisions described in this prospectus apply to a particular series of debt securities. You should read the actual indenture if you do not fully understand a term or the way we use it in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer senior or subordinated debt securities. Each series of debt securities may have different terms. The senior debt securities will
be issued under one or more senior indentures, dated as of a date prior to such issuance, between us and the trustee identified in the applicable prospectus supplement, as amended or supplemented from time to time. We will refer to any such
indenture throughout this prospectus as the &#147;senior indenture.&#148; Any subordinated debt securities will be issued under one or more separate indentures, dated as of a date prior to such issuance, between us and the trustee identified in the
applicable prospectus supplement, as amended or supplemented from time to time. We will refer to any such indenture throughout this prospectus as the &#147;subordinated indenture&#148; and to the trustee under the senior or subordinated indenture as
the &#147;trustee.&#148; The senior indenture and the subordinated indenture are sometimes collectively referred to in this prospectus as the &#147;indentures.&#148; The indentures will be subject to and governed by the Trust Indenture Act of 1939,
as amended. We included copies of the forms of the indentures as exhibits to our registration statement and they are incorporated into this prospectus by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue debt securities at a discount from their principal amount, then, for purposes of calculating the aggregate initial offering price
of the offered securities issued under this prospectus, we will include only the initial offering price of the debt securities and not the principal amount of the debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have summarized below the material provisions of the indentures and the debt securities, or indicated which material provisions will be
described in the related prospectus supplement. The prospectus supplement relating to any particular securities offered will describe the specific terms of the securities, which may be in addition to or different from the general terms summarized in
this prospectus. Because the summary in this prospectus and in any prospectus supplement does not contain all of the information that you may find useful, you should read the documents relating to the securities that are described in this prospectus
or in any applicable prospectus supplement. Please read &#147;Where You Can Find More Information&#148; to find out how you can obtain a copy of those documents. Except as otherwise indicated, the terms of the indentures are identical. As used under
this caption, the term &#147;debt securities&#148; includes the debt securities being offered by this prospectus and all other debt securities issued by us under the indentures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">do not limit the amount of debt securities that we may issue; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow us to issue debt securities in one or more series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">do not require us to issue all of the debt securities of a series at the same time; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">allow us to reopen a series to issue additional debt securities without the consent of the holders of the debt
securities of such series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide that the debt securities will be unsecured, except as may be set forth in the applicable prospectus
supplement. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we give you different information in the applicable prospectus supplement, the senior debt
securities will be unsubordinated obligations and will rank equally with all of our other senior unsecured and unsubordinated </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
indebtedness. Payments on the subordinated debt securities will be subordinated to the prior payment in full of all of our senior indebtedness, as described under &#147;Description of Debt
Securities&#151;Subordination&#148; and in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that we may, but need not,
designate more than one trustee under an indenture. Any trustee under an indenture may resign or be removed and a successor trustee may be appointed to act with respect to the series of debt securities administered by the resigning or removed
trustee. If two or more persons are acting as trustee with respect to different series of debt securities, each trustee shall be a trustee of a trust under the applicable indenture separate and apart from the trust administered by any other trustee.
Except as otherwise indicated in this prospectus, any action described in this prospectus to be taken by each trustee may be taken by each trustee with respect to, and only with respect to, the one or more series of debt securities for which it is
trustee under the applicable indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement for each offering will provide the following terms, where applicable:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the debt securities and whether they are senior or subordinated; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the aggregate principal amount of the debt securities being offered, the aggregate principal amount of the debt
securities outstanding as of the most recent practicable date and any limit on their aggregate principal amount, including the aggregate principal amount of debt securities authorized; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price at which the debt securities will be issued, expressed as a percentage of the principal and, if other
than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof or, if applicable, the portion of the principal amount of such debt securities that is convertible into
common stock or other securities of ours or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if convertible, the terms on which such debt securities are convertible, including the initial conversion price
or rate and the conversion period and any applicable limitations on the ownership or transferability of common stock or other securities of ours received on conversion; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, or the method for determining the date or dates, on which the principal of the debt securities
will be payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the fixed or variable interest rate or rates of the debt securities, or the method by which the interest rate or
rates is determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, or the method for determining the date or dates, from which interest will accrue;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which interest will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the record dates for interest payment dates, or the method by which such dates will be determined;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the persons to whom interest will be payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the basis upon which interest will be calculated if other than that of a
<FONT STYLE="white-space:nowrap">360-day</FONT> year of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any make-whole amount, which is the amount in addition to principal and interest that is required to be paid to
the holder of a debt security as a result of any optional redemption or accelerated payment of such debt security, or the method for determining the make-whole amount; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where the principal of, and any premium or make-whole amount, and interest on, the debt
securities will be payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where the debt securities may be surrendered for registration of transfer or conversion or exchange;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">where notices or demands to or upon us in respect of the debt securities and the applicable indenture may be
served; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the times, prices and other terms and conditions upon which we may redeem the debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any obligation we have to redeem, repay or purchase the debt securities pursuant to any sinking fund or analogous
provision or at the option of holders of the debt securities, and the times and prices at which we must redeem, repay or purchase the debt securities as a result of such obligation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency or currencies in which the debt securities are denominated and payable if other than United States
dollars, which may be a foreign currency or units of two or more foreign currencies or a composite currency or currencies and the terms and conditions relating thereto, and the manner of determining the equivalent of such foreign currency in United
States dollars; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the principal of, and any premium or make-whole amount, or interest on, the debt securities of the series
are to be payable, at our election or at the election of a holder, in a currency or currencies other than that in which the debt securities are denominated or stated to be payable, and other related terms and conditions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the amount of payments of principal of, and any premium or make-whole amount, or interest on, the debt
securities may be determined according to an index, formula or other method and how such amounts will be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be in registered form, bearer form, or both, and (i)&nbsp;if in registered form,
the person to whom any interest shall be payable, if other than the person in whose name the security is registered at the close of business on the regular record date for such interest, or (ii)&nbsp;if in bearer form, the manner in which, or the
person to whom, any interest on the security shall be payable if otherwise than upon presentation and surrender upon maturity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions applicable to the offer, sale or delivery of securities in bearer form and the terms upon which
securities in bearer form of the series may be exchanged for securities in registered form of the series and vice versa, if permitted by applicable laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether any debt securities of the series are to be issuable initially in temporary global form and whether any
debt securities of the series are to be issuable in permanent global form with or without coupons and, if so, whether beneficial owners of interests in any such permanent global security may, or shall be required to, exchange their interests for
other debt securities of the series, and the manner in which interest shall be paid; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the identity of the depositary for securities in registered form, if such series are to be issuable as a global
security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date as of which any debt securities in bearer form or in temporary global form shall be dated if other than
the original issuance date of the first security of the series to be issued; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability, if any, of the defeasance and covenant defeasance provisions described in this prospectus or
in the applicable indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and under what circumstances we will pay any additional amounts on the debt securities in respect of any
tax, assessment or governmental charge and, if so, whether we will have the option to redeem the debt securities in lieu of making such a payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and under what circumstances the debt securities being offered are convertible into common stock or other
securities of ours, as the case may be, including the conversion price or rate and the manner or calculation thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the circumstances, if any, specified in the applicable prospectus supplement, under which beneficial owners of
interests in the global security may obtain definitive debt securities and the manner in which payments on a permanent global debt security will be made if any debt securities are issuable in temporary or permanent global form;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions granting special rights to holders of securities upon the occurrence of such events as specified
in the applicable prospectus supplement; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the debt securities of such series are to be issuable in definitive form only upon receipt of certain
certificates or other documents or satisfaction of other conditions, then the form and/or terms of such certificates, documents or conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name of the applicable trustee and the nature of any material relationship with us or any of our affiliates,
and the percentage of debt securities of the class necessary to require the trustee to take action; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any deletions from, modifications of or additions to our events of default or covenants with regard to such debt
securities and any change in the right of any trustee or any of the holders to declare the principal amount of any of such debt securities due and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">applicable CUSIP numbers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of such debt securities not inconsistent with the provisions of the applicable indenture.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities that provide for less than the entire principal amount thereof to be payable upon
declaration of acceleration of the maturity of the debt securities. We refer to any such debt securities throughout this prospectus as &#147;original issue discount securities.&#148; The applicable prospectus supplement will describe the United
States federal income tax consequences and other relevant considerations applicable to original issue discount securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also may
issue indexed debt securities. Payments of principal of, and premium and interest on, indexed debt securities are determined with reference to the rate of exchange between the currency or currency unit in which the debt security is denominated and
any other currency or currency unit specified by us, to the relationship between two or more currencies or currency units or by other similar methods or formulas specified in the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described under &#147;Merger, Consolidation or Sale of Assets&#148; or as may be set forth in any prospectus supplement, the debt
securities will not contain any provisions that (i)&nbsp;would limit our ability to incur indebtedness or (ii)&nbsp;would afford holders of debt securities protection in the event of (a)&nbsp;a highly leveraged or similar transaction involving us,
or (b)&nbsp;a change of control or reorganization, restructuring, merger or similar transaction involving us that may adversely affect the holders of the debt securities. In the future, we may enter into transactions, such as the sale of all or
substantially all of our assets or a merger or consolidation, that may have an adverse effect on our ability to service our indebtedness, including the debt securities, by, among other things, substantially reducing or eliminating our assets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our governing instruments do not define the term &#147;substantially all&#148; as it relates to the sale of assets. Additionally, Delaware
cases interpreting the term &#147;substantially all&#148; rely upon the facts and circumstances of each particular case. Consequently, to determine whether a sale of &#147;substantially all&#148; of our assets has occurred, a holder of debt
securities must review the financial and other information that we have disclosed to the public. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide you with more
information in the applicable prospectus supplement regarding any deletions, modifications, or additions to the events of default or covenants that are described below, including any addition of a covenant or other provision providing event risk or
similar protection. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we give you different information in the applicable prospectus supplement, the principal of, and any premium or make-whole amount, and
interest on, any series of the debt securities will be payable at the corporate trust office of the trustee. We will provide you with the address of the trustee in the applicable prospectus supplement. We may also pay interest by mailing a check to
the address of the person entitled to it as it appears in the applicable register for the debt securities or by wire transfer of funds to that person at an account maintained within the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All monies that we pay to a paying agent or a trustee for the payment of the principal of,
and any premium or make-whole amount, or interest on, any debt security will be repaid to us if unclaimed at the end of two years after the obligation underlying payment becomes due and payable. After funds have been returned to us, the holder of
the debt security may look only to us for payment, without payment of interest for the period which we hold the funds. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Denomination, Interest,
Registration and Transfer </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise described in the applicable prospectus supplement, the debt securities of any series
will be issuable in denominations of $1,000 and integral multiples of $1,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the limitations imposed upon debt securities
that are evidenced by a computerized entry in the records of a depository company rather than by physical delivery of a note, a holder of debt securities of any series may: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exchange them for any authorized denomination of other debt securities of the same series and of a like aggregate
principal amount and kind upon surrender of such debt securities at the corporate trust office of the applicable trustee or at the office of any transfer agent that we designate for such purpose; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">surrender them for registration of transfer or exchange at the corporate trust office of the applicable trustee
or at the office of any transfer agent that we designate for such purpose. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Every debt security surrendered for
registration of transfer or exchange must be duly endorsed or accompanied by a written instrument of transfer satisfactory to the applicable trustee or transfer agent. Payment of a service charge will not be required for any registration of transfer
or exchange of any debt securities, but we or the trustee may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. If in addition to the applicable trustee, the applicable prospectus
supplement refers to any transfer agent initially designated by us for any series of debt securities, we may at any time rescind the designation of any such transfer agent or approve a change in the location through which any such transfer agent
acts, except that we will be required to maintain a transfer agent in each place of payment for such series. We may at any time designate additional transfer agents for any series of debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we, nor any trustee, will be required to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of or exchange debt securities of any series during a period beginning at the
opening of business 15 days before the day that the notice of redemption of any debt securities selected for redemption is mailed and ending at the close of business on the day of such mailing; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt security, or portion thereof, so selected for redemption, in whole
or in part, except the unredeemed portion of any debt security being redeemed in part; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of or exchange any debt security that has been surrendered for repayment at the
option of the holder, except the portion, if any, of such debt security not to be so repaid. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Merger, Consolidation or Sale of
Assets </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures provide that we may, without the consent of the holders of any outstanding debt securities,
(i)&nbsp;consolidate with, (ii)&nbsp;sell, lease or convey all or substantially all of our assets to, or (iii)&nbsp;merge with or into, any other entity provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">either we are the continuing entity, or the successor entity, if other than us, assumes the obligations
(a)&nbsp;to pay the principal of, and any premium or make-whole amount, and interest on, all of the debt securities and (b)&nbsp;to duly perform and observe all of the covenants and conditions contained in each indenture; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">after giving effect to the transaction, there is no event of default under the indentures and no event which,
after notice or the lapse of time, or both, would become such an event of default, occurs and continues; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an officers&#146; certificate and legal opinion covering such conditions are delivered to each applicable
trustee. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Covenants </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Existence</I>. Except as described under &#147;Merger, Consolidation or Sale of Assets,&#148; the indentures require us to do or cause to be
done all things necessary to preserve and keep in full force and effect our existence, rights and franchises. However, the indentures do not require us to preserve any right or franchise if we determine that any right or franchise is no longer
desirable in the conduct of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Payment of taxes and other claims</I>. The indentures require us to pay, discharge or cause
to be paid or discharged, before they become delinquent (i)&nbsp;all taxes, assessments and governmental charges levied or imposed on us, and (ii)&nbsp;all lawful claims for labor, materials and supplies which, if unpaid, might by law become a lien
upon our property. However, we will not be required to pay, discharge or cause to be paid or discharged any such tax, assessment, charge or claim whose amount, applicability or validity is being contested in good faith by appropriate proceedings.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Provision of financial information</I>. The indentures require us to (i)&nbsp;within 15 days of each of the respective dates by which
we are required to file our annual reports, quarterly reports and other documents with the SEC, file with the trustee copies of the annual report, quarterly report and other documents that we file with the SEC under Section&nbsp;13 or 15(d) of the
Exchange Act, (ii)&nbsp;file with the trustee and the SEC any additional information, documents and reports regarding compliance by us with the conditions and covenants of the indentures, as required, (iii)&nbsp;within 30 days after the filing with
the trustee, mail to all holders of debt securities, as their names and addresses appear in the applicable register for such debt securities, without cost to such holders, summaries of any documents and reports required to be filed by us pursuant to
(i)&nbsp;and (ii)&nbsp;above, and (iv)&nbsp;supply, promptly upon written request and payment of the reasonable cost of duplication and delivery, copies of such documents to any prospective holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Additional covenants</I>. The applicable prospectus supplement will set forth any of our additional covenants relating to any series of
debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Events of Default, Notice and Waiver </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement states otherwise, when we refer to &#147;events of default&#148; as defined in the indentures with
respect to any series of debt securities, we mean: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of any installment of interest on any debt security of such series continuing for 30 days;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of principal of, or any premium or make-whole amount on, any debt security of such series
for five business days at its stated maturity; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in making any sinking fund payment as required for any debt security of such series for five business
days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the performance or breach of any covenant or warranty in the debt securities or in the indenture by us
continuing for 60 days after written notice as provided in the applicable indenture, but not of a covenant added to the indenture solely for the benefit of a series of debt securities issued thereunder other than such series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a default under any bond, debenture, note, mortgage, indenture or instrument: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">having an aggregate principal amount of at least $30,000,000; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">under which there may be issued, secured or evidenced any existing or later created indebtedness for money
borrowed by us, if we are directly responsible or liable as obligor or guarantor, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">if the default results in the
indebtedness becoming or being declared due and payable prior to the date it otherwise would have, without such indebtedness having been discharged, or such acceleration having been rescinded or annulled, within 30 days after notice to the issuing
company specifying such default. Such notice shall be given to us by the trustee, or to us and the trustee by the holders of at least 10% in principal amount of the outstanding debt securities of that series. The written notice shall specify such
default and require us to cause such indebtedness to be discharged or cause such acceleration to be rescinded or annulled and shall state that such notice is a &#147;Notice of Default&#148; under such indenture; </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">bankruptcy, insolvency or reorganization, or court appointment of a receiver, liquidator or trustee of us; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other event of default provided with respect to a particular series of debt securities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default occurs and is continuing with respect to debt securities of any series outstanding, then the
applicable trustee or the holders of 25% or more in principal amount of the debt securities of that series will have the right to declare the principal amount of all the debt securities of that series to be due and payable. If the debt securities of
that series are original issue discount securities or indexed securities, then the applicable trustee or the holders of 25% or more in principal amount of the debt securities of that series will have the right to declare the portion of the principal
amount as may be specified in the terms thereof to be due and payable. However, at any time after such a declaration of acceleration has been made, but before a judgment or decree for payment of the money due has been obtained by the applicable
trustee, the holders of at least a majority in principal amount of outstanding debt securities of such series or of all debt securities then outstanding under the applicable indenture may rescind and annul such declaration and its consequences if:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have deposited with the applicable trustee all required payments of the principal, any premium or make-whole
amount, interest and, to the extent permitted by law, interest on overdue installment of interest, plus applicable fees, expenses, disbursements and advances of the applicable trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all events of default, other than the <FONT STYLE="white-space:nowrap">non-payment</FONT> of accelerated
principal, or a specified portion thereof, and any premium or make-whole amount, have been cured or waived. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indentures also provide that the holders of at least a majority in principal amount of the outstanding debt securities of any series or of all debt securities then outstanding under the applicable indenture may, on behalf of all holders, waive any
past default with respect to such series and its consequences, except a default: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the payment of the principal, any premium or make-whole amount, or interest; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in respect of a covenant or provision contained in the applicable indenture that cannot be modified or amended
without the consent of the holders of the outstanding debt security that is affected by the default; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in respect of a covenant or provision for the benefit or protection of the trustee, without its express written
consent. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures require each trustee to give notice to the holders of debt securities within 90 days of a
default unless such default has been cured or waived. However, the trustee may withhold notice if specified persons of such trustee consider such withholding to be in the interest of the holders of debt securities. The trustee may not withhold
notice of a default in the payment of principal, any premium or interest on any debt security of such series or in the payment of any sinking fund installment in respect of any debt security of such series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures provide that holders of debt securities of any series may not institute any proceedings, judicial or otherwise, with respect to
such indenture or for any remedy under the indenture, unless the trustee </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
fails to act for a period of 60 days after the trustee has received a written request to institute proceedings in respect of an event of default from the holders of 25% or more in principal
amount of the outstanding debt securities of such series, as well as an offer of indemnity reasonably satisfactory to the trustee. However, this provision will not prevent any holder of debt securities from instituting suit for the enforcement of
payment of the principal of, and any premium or make-whole amount, and interest on, such debt securities at the respective due dates thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures provide that, subject to provisions in each indenture relating to its duties in the case of a default, a trustee has no
obligation to exercise any of its rights or powers at the request or direction of any holders of any series of debt securities then outstanding under the indenture, unless the holders have offered to the trustee reasonable security or indemnity. The
holders of at least a majority in principal amount of the outstanding debt securities of any series or of all debt securities then outstanding under an indenture shall have the right to direct the time, method and place of conducting any proceeding
for any remedy available to the applicable trustee, or of exercising any trust or power conferred upon such trustee. However, a trustee may refuse to follow any direction which: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">is in conflict with any law or the applicable indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may involve the trustee in personal liability; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">may be unduly prejudicial to the holders of debt securities of the series not joining the proceeding.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Within 120 days after the close of each fiscal year, we will be required to deliver to each trustee a certificate,
signed by one of our several specified officers, stating whether or not that officer has knowledge of any default under the applicable indenture. If the officer has knowledge of any default, the notice must specify the nature and status of the
default. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification of the Indentures </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures provide that modifications and amendments may be made only with the consent of the affected holders of a majority in principal
amount of all outstanding debt securities issued under that indenture. However, no such modification or amendment may, without the consent of the holders of the debt securities affected by the modification or amendment: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the stated maturity of the principal of, or any premium or make-whole amount on, or any installment of
principal of or interest on, any such debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal amount of, the rate or amount of interest on, or any premium or make-whole amount payable on
redemption of, any such debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of principal of an original issue discount security that would be due and payable upon
declaration of acceleration of the maturity thereof or would be provable in bankruptcy, or adversely affect any right of repayment of the holder of any such debt security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">change the place of payment or the coin or currency for payment of principal of, or any premium or make-whole
amount, or interest on, any such debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impair the right to institute suit for the enforcement of any payment on or with respect to any such debt
security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage in principal amount of any outstanding debt securities necessary to modify or amend the
applicable indenture with respect to such debt securities, to waive compliance with particular provisions thereof or defaults and consequences thereunder or to reduce the quorum or voting requirements set forth in the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">modify any of the foregoing provisions or any of the provisions relating to the waiver of particular past
defaults or covenants, except to increase the required percentage to effect such action or to provide that some of the other provisions may not be modified or waived without the consent of the holder of such debt security. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in aggregate principal amount of the outstanding debt securities
of each series may, on behalf of all holders of debt securities of that series, waive, insofar as that series is concerned, our compliance with material restrictive covenants of the applicable indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and our respective trustee may make modifications and amendments of an indenture without the consent of any holder of debt securities for
any of the following purposes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence the succession of another person to us as obligor under such indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants for the benefit of the holders of all or any series of debt securities or to surrender
any right or power conferred upon us in such indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add events of default for the benefit of the holders of all or any series of debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add or change any provisions of an indenture (i)&nbsp;to change or eliminate restrictions on the payment of
principal of, or premium or make-whole amount, or interest on, debt securities in bearer form, or (ii)&nbsp;to permit or facilitate the issuance of debt securities in uncertificated form, provided that such action shall not adversely affect the
interests of the holders of the debt securities of any series in any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to change or eliminate any provisions of an indenture, provided that any such change or elimination shall become
effective only when there are no debt securities outstanding of any series created prior thereto which are entitled to the benefit of such provision; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to secure the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to establish the form or terms of debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the acceptance of appointment by a successor trustee or facilitate the administration of the
trusts under an indenture by more than one trustee; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in an indenture, provided that such action shall not adversely
affect the interests of holders of debt securities of any series issued under such indenture; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to supplement any of the provisions of an indenture to the extent necessary to permit or facilitate defeasance
and discharge of any series of such debt securities, provided that such action shall not adversely affect the interests of the holders of the outstanding debt securities of any series. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures provide
that in determining whether the holders of the requisite principal amount of outstanding debt securities of a series have given any request, demand, authorization, direction, notice, consent or waiver under the indentures or whether a quorum is
present at a meeting of holders of debt securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of an original issue discount security that shall be deemed to be outstanding shall be the
amount of the principal thereof that would be due and payable as of the date of such determination upon declaration of acceleration of the maturity thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of any debt security denominated in a foreign currency that shall be deemed outstanding
shall be the United States dollar equivalent, determined on the issue date for such debt security, of the principal amount or, in the case of an original issue discount security, the United States dollar equivalent on the issue date of such debt
security of the amount determined as provided in the preceding bullet point; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of an indexed security that shall be deemed outstanding shall be the principal face amount
of such indexed security at original issuance, unless otherwise provided for such indexed security under such indenture; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">debt securities owned by us or any other obligor upon the debt securities or by any affiliate of ours or of such
other obligor shall be disregarded. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures contain provisions for convening meetings of the holders of debt securities
of a series. A meeting will be permitted to be called at any time by the applicable trustee, and also, upon request, by us or the holders of at least 25% in principal amount of the outstanding debt securities of such series, in any such case upon
notice given as provided in such indenture. Except for any consent that must be given by the holder of each debt security affected by the modifications and amendments of an indenture described above, any resolution presented at a meeting or
adjourned meeting duly reconvened at which a quorum is present may be adopted by the affirmative vote of the holders of a majority of the aggregate principal amount of the outstanding debt securities of that series represented at such meeting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the preceding paragraph, except as referred to above, any resolution relating to a request, demand, authorization, direction,
notice, consent, waiver or other action that may be made, given or taken by the holders of a specified percentage, which is less than a majority of the aggregate principal amount of the outstanding debt securities of a series, may be adopted at a
meeting or adjourned meeting duly reconvened at which a quorum is present by the affirmative vote of such specified percentage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any
resolution passed or decision taken at any properly held meeting of holders of debt securities of any series will be binding on all holders of such series. The quorum at any meeting called to adopt a resolution, and at any reconvened meeting, will
be persons holding or representing a majority in principal amount of the outstanding debt securities of a series. However, if any action is to be taken relating to a consent or waiver which may be given by the holders of at least a specified
percentage in principal amount of the outstanding debt securities of a series, the persons holding such percentage will constitute a quorum. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing provisions, the indentures provide that if any action is to be taken at a meeting with respect to any request,
demand, authorization, direction, notice, consent, waiver or other action that such indenture expressly provides may be made, given or taken by the holders of a specified percentage in principal amount of all outstanding debt securities affected by
such action, or of the holders of such series and one or more additional series: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">there shall be no minimum quorum requirement for such meeting; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of the outstanding debt securities of such series that vote in favor of such request,
demand, authorization, direction, notice, consent, waiver or other action shall be taken account in determining whether such request, demand, authorization, direction, notice, consent, waiver or other action has been made, given or taken under such
indenture. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Subordination </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the applicable prospectus supplement, subordinated debt securities will be subject to the following subordination
provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon any distribution to our creditors in a liquidation, dissolution or reorganization, the payment of the principal of and
interest on any subordinated debt securities will be subordinated to the extent provided in the applicable indenture in right of payment to the prior payment in full of all senior debt. However, our obligation to make payments of the principal of
and interest on such subordinated debt securities otherwise will not be affected. No payment of principal or interest will be permitted to be made on subordinated debt securities at any time if a default on senior debt exists that permits the
holders of such senior debt to accelerate its maturity and the default is the subject of judicial proceedings or we receive notice of the default. After all senior debt is paid in full and until the subordinated debt securities are paid in full,
holders of subordinated debt securities will be subrogated to the rights of holders of senior debt to the extent that distributions otherwise payable to holders of subordinated debt securities have been applied to the payment of senior debt. The
subordinated indenture will not restrict the amount of senior debt or other indebtedness of ours. As a result of these subordination provisions, in the event of a distribution of assets upon insolvency, holders of subordinated debt securities may
recover less, ratably, than our general creditors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The term &#147;senior debt&#148; will be defined in the applicable indenture as the
principal of and interest on, or substantially similar payments to be made by us in respect of, other outstanding indebtedness, whether outstanding at the date of execution of the applicable indenture or subsequently incurred, created or assumed.
The prospectus supplement may include a description of additional terms implementing the subordination feature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No restrictions will be
included in any indenture relating to subordinated debt securities upon the creation of additional senior debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If this prospectus is
being delivered in connection with the offering of a series of subordinated debt securities, the accompanying prospectus supplement or the information incorporated in this prospectus by reference will set forth the approximate amount of senior debt
outstanding as of the end of our most recent fiscal quarter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Discharge, Defeasance and Covenant Defeasance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, the indentures allow us to discharge our obligations to holders of any
series of debt securities issued under any indenture when: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">either (i)&nbsp;all securities of such series have already been delivered to the applicable trustee for
cancellation; or (ii)&nbsp;all securities of such series have not already been delivered to the applicable trustee for cancellation but (a)&nbsp;have become due and payable, (b)&nbsp;will become due and payable within one year, or (c)&nbsp;if
redeemable at our option, are to be redeemed within one year, and we have irrevocably deposited with the applicable trustee, in trust, funds in such currency or currencies, currency unit or units or composite currency or currencies in which such
debt securities are payable, an amount sufficient to pay the entire indebtedness on such debt securities in respect of principal and any premium or make-whole amount, and interest to the date of such deposit if such debt securities have become due
and payable or, if they have not, to the stated maturity or redemption date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we have paid or caused to be paid all other sums payable; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an officers&#146; certificate and an opinion of counsel stating the conditions to discharging the debt securities
have been satisfied has been delivered to the trustee. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus
supplement, the indentures provide that, upon our irrevocable deposit with the applicable trustee, in trust, of an amount, in such currency or currencies, currency unit or units or composite currency or currencies in which such debt securities are
payable at stated maturity, or government obligations, or both, applicable to such debt securities, which through the scheduled payment of principal and interest in accordance with their terms will provide money in an amount sufficient to pay the
principal of, and any premium or make-whole amount, and interest on, such debt securities, and any mandatory sinking fund or analogous payments thereon, on the scheduled due dates therefor, the issuing company may elect either: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to defease and be discharged from any and all obligations with respect to such debt securities; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to be released from its obligations with respect to such debt securities under the applicable indenture or, if
provided in the applicable prospectus supplement, its obligations with respect to any other covenant, and any omission to comply with such obligations shall not constitute an event of default with respect to such debt securities.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, we may not elect to defease and be discharged from the obligation to pay any additional
amounts upon the occurrence of particular events of tax, assessment or governmental charge with respect to payments on such debt securities and the obligations to register the transfer or exchange of such debt securities, to replace temporary or
mutilated, destroyed, lost or stolen debt securities, to maintain an office or agency in respect of such debt securities, or to hold monies for payment in trust. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures only permit us to establish the trust described in the paragraph above if,
among other things, we have delivered to the applicable trustee an opinion of counsel to the effect that the holders of such debt securities will not recognize income, gain or loss for United States federal income tax purposes as a result of such
defeasance or covenant defeasance and will be subject to United States federal income tax on the same amounts, in the same manner and at the same times as would have been the case if such defeasance or covenant defeasance had not occurred. Such
opinion of counsel, in the case of defeasance, will be required to refer to and be based upon a ruling received from or published by the Internal Revenue Service or a change in applicable United States federal income tax law occurring after the date
of the indenture. In the event of such defeasance, the holders of such debt securities would be able to look only to such trust fund for payment of principal, any premium or make-whole amount, and interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we use the term &#147;government obligations,&#148; we mean securities that are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">direct obligations of the United States or the government that issued the foreign currency in which the debt
securities of a particular series are payable, for the payment of which its full faith and credit is pledged; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">obligations of a person controlled or supervised by and acting as an agency or instrumentality of the United
States or other government that issued the foreign currency in which the debt securities of such series are payable, the payment of which is unconditionally guaranteed as a full faith and credit obligation by the United States or such other
government, which are not callable or redeemable at the option of the issuer thereof and shall also include a depository receipt issued by a bank or trust company as custodian with respect to any such government obligation or a specific payment of
interest on or principal of any such government obligation held by such custodian for the account of the holder of a depository receipt. However, except as required by law, such custodian is not authorized to make any deduction from the amount
payable to the holder of such depository receipt from any amount received by the custodian in respect of the government obligation or the specific payment of interest on or principal of the government obligation evidenced by such depository receipt.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the applicable prospectus supplement, if after we have deposited funds and/or government
obligations to effect defeasance or covenant defeasance with respect to debt securities of any series, (i)&nbsp;the holder of a debt security of such series is entitled to, and does, elect under the terms of the applicable indenture or the terms of
such debt security to receive payment in a currency, currency unit or composite currency other than that in which such deposit has been made in respect of such debt security, or (ii)&nbsp;a conversion event occurs in respect of the currency,
currency unit or composite currency in which such deposit has been made, the indebtedness represented by such debt security will be deemed to have been, and will be, fully discharged and satisfied through the payment of the principal of, and premium
or make-whole amount, and interest on, such debt security as they become due out of the proceeds yielded by converting the amount so deposited in respect of such debt security into the currency, currency unit or composite currency in which such debt
security becomes payable as a result of such election or such cessation of usage based on the applicable market exchange rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">When we
use the term &#147;conversion event,&#148; we mean the cessation of use of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a currency, currency unit or composite currency both by the government of the country that issued such currency
and for the settlement of transactions by a central bank or other public institutions of or within the international banking community; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the European Currency Unit both within the European Monetary System and for the settlement of transactions by
public institutions of or within the European Communities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any currency unit or composite currency other than the European Currency Unit for the purposes for which it was
established. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise provided in the applicable prospectus supplement, all payments of principal
of, and any premium or make-whole amount, and interest on, any debt security that is payable in a foreign currency that ceases to be used by its government of issuance shall be made in United States dollars. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that (i)&nbsp;we effect covenant defeasance with respect to any debt securities and (ii)&nbsp;those debt securities are declared
due and payable because of the occurrence of any event of default, the amount in the currency, currency unit or composite currency in which such debt securities are payable, and government obligations on deposit with the applicable trustee, will be
sufficient to pay amounts due on such debt securities at the time of their stated maturity but may not be sufficient to pay amounts due on such debt securities at the time of the acceleration resulting from such event of default. However, the
issuing company would remain liable to make payments of any amounts due at the time of acceleration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement
may further describe the provisions, if any, permitting such defeasance or covenant defeasance, including any modifications to the provisions described above, with respect to the debt securities of or within a particular series. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Conversion Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms and
conditions, if any, upon which the debt securities are convertible into common stock or other securities of ours will be set forth in the applicable prospectus supplement. The terms will include whether the debt securities are convertible into
shares of common stock or other securities of ours, the conversion price, or manner of calculation thereof, the conversion period, provisions as to whether conversion will be at the issuing company&#146;s option or the option of the holders, the
events requiring an adjustment of the conversion price and provisions affecting conversion in the event of the redemption of the debt securities and any restrictions on conversion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Global Securities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt
securities of a series may be issued in whole or in part in the form of one or more global securities that will be deposited with, or on behalf of, a depository identified in the applicable prospectus supplement relating to such series. Global
securities, if any, issued in the United States are expected to be deposited with The Depository Trust Company, or DTC, as depository. We may issue global securities in either registered or bearer form and in either temporary or permanent form. We
will describe the specific terms of the depository arrangement with respect to a series of debt securities in the applicable prospectus supplement relating to such series. We expect that unless the applicable prospectus supplement provides
otherwise, the following provisions will apply to depository arrangements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Once a global security is issued, the depository for such
global security or its nominee will credit on its book-entry registration and transfer system the respective principal amounts of the individual debt securities represented by such global security to the accounts of participants that have accounts
with such depository. Such accounts shall be designated by the underwriters, dealers or agents with respect to such debt securities or by us if we offer such debt securities directly. Ownership of beneficial interests in such global security will be
limited to participants with the depository or persons that may hold interests through those participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that, under
procedures established by DTC, ownership of beneficial interests in any global security for which DTC is the depository will be shown on, and the transfer of that ownership will be effected only through, records maintained by DTC or its nominee,
with respect to beneficial interests of participants with the depository, and records of participants, with respect to beneficial interests of persons who hold through participants with the depository. Neither we nor the trustee will have any
responsibility or liability for any aspect of the records of DTC or for maintaining, supervising or reviewing any records of DTC or any of its participants relating to beneficial ownership interests in the debt securities. The laws of some states
require that certain purchasers of securities take physical delivery of such securities in definitive form. Such limits and laws may impair the ability to own, pledge or transfer beneficial interest in a global security. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">So long as the depository for a global security or its nominee is the registered owner of
such global security, such depository or such nominee, as the case may be, will be considered the sole owner or holder of the debt securities represented by the global security for all purposes under the applicable indenture. Except as described
below or in the applicable prospectus supplement, owners of beneficial interest in a global security will not be entitled to have any of the individual debt securities represented by such global security registered in their names, will not receive
or be entitled to receive physical delivery of any such debt securities in definitive form and will not be considered the owners or holders thereof under the applicable indenture. Beneficial owners of debt securities evidenced by a global security
will not be considered the owners or holders thereof under the applicable indenture for any purpose, including with respect to the giving of any direction, instructions or approvals to the trustee under the indenture. Accordingly, each person owning
a beneficial interest in a global security with respect to which DTC is the depository must rely on the procedures of DTC and, if such person is not a participant with the depository, on the procedures of the participant through which such person
owns its interests, to exercise any rights of a holder under the applicable indenture. We understand that, under existing industry practice, if DTC requests any action of holders or if an owner of a beneficial interest in a global security desires
to give or take any action which a holder is entitled to give or take under the applicable indenture, DTC would authorize the participants holding the relevant beneficial interest to give or take such action, and such participants would authorize
beneficial owners through such participants to give or take such actions or would otherwise act upon the instructions of beneficial owners holding through them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Payments of principal of, and any premium or make-whole amount, and interest on, individual debt securities represented by a global security
registered in the name of a depository or its nominee will be made to or at the direction of the depository or its nominee, as the case may be, as the registered owner of the global security under the applicable indenture. Under the terms of the
applicable indenture, we and the trustee may treat the persons in whose name debt securities, including a global security, are registered as the owners thereof for the purpose of receiving such payments. Consequently, neither we nor the trustee have
or will have any responsibility or liability for the payment of such amounts to beneficial owners of debt securities including principal, any premium or make-whole amount, or interest. We believe, however, that it is currently the policy of DTC to
immediately credit the accounts of relevant participants with such payments, in amounts proportionate to their respective holdings of beneficial interests in the relevant global security as shown on the records of DTC or its nominee. We also expect
that payments by participants to owners of beneficial interests in such global security held through such participants will be governed by standing instructions and customary practices, as is the case with securities held for the account of
customers in bearer form or registered in street name, and will be the responsibility of such participants. Redemption notices with respect to any debt securities represented by a global security will be sent to the depository or its nominee. If
less than all of the debt securities of any series are to be redeemed, we expect the depository to determine the amount of the interest of each participant in such debt securities to be redeemed to be determined by lot. Neither we, the trustee, any
paying agent nor the security registrar for such debt securities will have any responsibility or liability for any aspect of the records relating to or payments made on account of beneficial ownership interests in the global security for such debt
securities or for maintaining any records with respect thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the trustee will be liable for any delay by the holders of
a global security or the depository in identifying the beneficial owners of debt securities, and we and the trustee may conclusively rely on, and will be protected in relying on, instructions from the holder of a global security or the depository
for all purposes. The rules applicable to DTC and its participants are on file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a depository for any debt securities is
at any time unwilling, unable or ineligible to continue as depository and we do not appoint a successor depository within 90 days, we will issue individual debt securities in exchange for the global security representing such debt securities. In
addition, we may at any time and at our sole discretion, subject to any limitations described in the applicable prospectus supplement relating to such debt securities, determine not to have any of such debt securities represented by one or more
global securities and in such event will issue individual debt securities in exchange for the global security or securities representing such debt securities. Individual debt securities so issued will be issued in denominations of $1,000 and
integral multiples of $1,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities of a series may also be issued in whole or in part in the form of one or
more bearer global securities that will be deposited with a depository, or with a nominee for such depository, identified in the applicable prospectus supplement. Any such bearer global securities may be issued in temporary or permanent form. The
specific terms and procedures, including the specific terms of the depositary arrangement, with respect to any portion of a series of debt securities to be represented by one or more bearer global securities will be described in the applicable
prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>No Recourse </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is no recourse under any obligation, covenant or agreement in the applicable indenture or with respect to any security against any of our
or our successor&#146;s past, present or future shareholders, employees, officers or directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_9"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplements, summarizes the
material terms and provisions of the warrants that we may offer under this prospectus and the related warrant agreements and warrant certificates. While the terms summarized below will apply generally to any warrants that we may offer, we will
describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. If we indicate in the prospectus supplement, the terms of any warrants offered under that prospectus supplement may differ from the terms
described below. Specific warrant agreements will contain additional important terms and provisions and will be incorporated by reference as an exhibit to the registration statement, which includes this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the
purchase of common stock, preferred stock and/or debt securities in one or more series. We may issue warrants independently or together with common stock, preferred stock and/or debt securities, and the warrants may be attached to or separate from
these securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will evidence each series of warrants by warrant certificates that we will issue under a separate warrant agreement.
We will enter into the warrant agreement with a warrant agent. We will indicate the name and address of the warrant agent in the applicable prospectus supplement relating to a particular series of warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of warrants, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date on and after which the warrants and the related securities will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreement and
the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the periods during which, and places at which, the warrants are exercisable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner of exercise; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreement and warrants may be modified; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">federal income tax consequences of holding or exercising the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_10"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units comprised of shares of common stock, shares of preferred stock, debt securities and warrants in any combination. We may
issue units in such amounts and in as many distinct series as we wish. This section outlines certain provisions of the units that we may issue. If we issue units, they will be issued under one or more unit agreements to be entered into between us
and a bank or other financial institution, as unit agent. The information described in this section may not be complete in all respects and is qualified entirely by reference to the unit agreement with respect to the units of any particular series.
The specific terms of any series of units offered will be described in the applicable prospectus supplement. If so described in a particular supplement, the specific terms of any series of units may differ from the general description of terms
presented below. We urge you to read any prospectus supplement related to any series of units we may offer, as well as the complete unit agreement and unit certificate that contain the terms of the units. If we issue units, forms of unit agreements
and unit certificates relating to such units will be incorporated by reference as exhibits to the registration statement, which includes this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each unit that we may issue will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the
holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time
or at any time before a specified date. The applicable prospectus supplement may describe: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation and terms of the units and of the securities comprising the units, including whether and under
what circumstances those securities may be held or transferred separately; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions of the governing unit agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which such units will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicable United States federal income tax considerations relating to the units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities
comprising the units; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units and of the securities comprising the units. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions described in this section, as well as those described under &#147;Description of Capital Stock,&#148; &#147;Description of Debt
Securities&#148; and &#147;Description of Warrants&#148; will apply to the securities included in each unit, to the extent relevant and as may be updated in any prospectus supplements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance in Series </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units in
such amounts and in as many distinct series as we wish. This section summarizes terms of the units that apply generally to all series. Most of the financial and other specific terms of your series will be described in the applicable prospectus
supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Unit Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
issue the units under one or more unit agreements to be entered into between us and a bank or other financial institution, as unit agent. We may add, replace or terminate unit agents from time to time. We will identify the unit agreement under which
each series of units will be issued and the unit agent under that agreement in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following provisions will generally apply to all unit agreements unless otherwise stated
in the applicable prospectus supplement: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification without Consent </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the applicable unit agent may amend any unit or unit agreement without the consent of any holder: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, including modifying any provisions of the governing unit agreement that differ from those
described below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to correct or supplement any defective or inconsistent provision; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any other change that we believe is necessary or desirable and will not adversely affect the interests of
the affected holders in any material respect. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not need any approval to make changes that affect only units to be
issued after the changes take effect. We may also make changes that do not adversely affect a particular unit in any material respect, even if they adversely affect other units in a material respect. In those cases, we do not need to obtain the
approval of the holder of the unaffected unit; we need only obtain any required approvals from the holders of the affected units. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Modification with
Consent </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not amend any particular unit or a unit agreement with respect to any particular unit unless we obtain the consent
of the holder of that unit, if the amendment would: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">impair any right of the holder to exercise or enforce any right under a security included in the unit if the
terms of that security require the consent of the holder to any changes that would impair the exercise or enforcement of that right; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the percentage of outstanding units or any series or class the consent of whose holders is required to
amend that series or class, or the applicable unit agreement with respect to that series or class, as described below. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any other change to a particular unit agreement and the units issued under that agreement would require the following approval: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the change affects only the units of a particular series issued under that agreement, the change must be
approved by the holders of a majority of the outstanding units of that series; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If the change affects the units of more than one series issued under that agreement, it must be approved by the
holders of a majority of all outstanding units of all series affected by the change, with the units of all the affected series voting together as one class for this purpose. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions regarding changes with majority approval also apply to changes affecting any securities issued under a unit agreement, as the
governing document. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In each case, the required approval must be given by written consent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Unit Agreements Will Not Be Qualified under Trust Indenture Act </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No unit agreement will be qualified as an indenture, and no unit agent will be required to qualify as a trustee, under the Trust Indenture Act.
Therefore, holders of units issued under unit agreements will not have the protections of the Trust Indenture Act with respect to their units. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mergers and Similar Transactions Permitted; No Restrictive Covenants or Events of Default </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unit agreements will not restrict our ability to merge or consolidate with, or sell our assets to, another corporation or other entity or
to engage in any other transactions. If at any time we merge or consolidate with, or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sell our assets substantially as an entirety to, another corporation or other entity, the successor entity will succeed to and assume our obligations under the unit agreements. We will then be
relieved of any further obligation under these agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unit agreements will not include any restrictions on our ability to put
liens on our assets, nor will they restrict our ability to sell our assets. The unit agreements also will not provide for any events of default or remedies upon the occurrence of any events of default. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Governing Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The unit agreements
and the units will be governed by Delaware law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Form, Exchange and Transfer </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the accompanying prospectus supplement states otherwise, we will issue each unit in global&#151;i.e., book-entry&#151;form only. Units
in book-entry form will be represented by a global security registered in the name of a depositary, which will be the holder of all the units represented by the global security. Those who own beneficial interests in a unit will do so through
participants in the depositary&#146;s system, and the rights of these indirect owners will be governed solely by the applicable procedures of the depositary and its participants. We will describe book-entry securities, and other terms regarding the
issuance and registration of the units in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the accompanying prospectus supplement states
otherwise, each unit and all securities comprising the unit will be issued in the same form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we issue any units in registered, <FONT
STYLE="white-space:nowrap">non-global</FONT> form, the following will apply to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The units will be issued in the denominations stated
in the applicable prospectus supplement. Holders may exchange their units for units of smaller denominations or combined into fewer units of larger denominations, as long as the total amount is not changed. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Holders may exchange or transfer their units at the office of the unit agent. Holders may also replace lost,
stolen, destroyed or mutilated units at that office. We may appoint another entity to perform these functions or perform them ourselves. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Holders will not be required to pay a service charge to transfer or exchange their units, but they may be
required to pay for any tax or other governmental charge associated with the transfer or exchange. The transfer or exchange, and any replacement, will be made only if our transfer agent is satisfied with the holder&#146;s proof of legal ownership.
The transfer agent may also require an indemnity before replacing any units. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we have the right to redeem, accelerate or settle any units before their maturity, and we exercise our right
as to less than all those units or other securities, we may block the exchange or transfer of those units during the period beginning 15 days before the day we mail the notice of exercise and ending on the day of that mailing, in order to freeze the
list of holders to prepare the mailing. We may also refuse to register transfers of or exchange any unit selected for early settlement, except that we will continue to permit transfers and exchanges of the unsettled portion of any unit being
partially settled. We may also block the transfer or exchange of any unit in this manner if the unit includes securities that are or may be selected for early settlement. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the depositary will be entitled to transfer or exchange a unit in global form, since it will be the sole holder of the unit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Payments and Notices </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In making payments and giving notices with respect to our units, we will follow the procedures as described in the applicable prospectus
supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_11"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus also relates to the possible resale from time to time by the stockholders named herein, who we refer to in this prospectus as
the &#147;selling stockholders,&#148; of up to an aggregate maximum amount of 12,445,646 shares of our common stock in one or more offerings, subject to market conditions and prices, liquidity objectives and other investment considerations. Such
shares of common stock were issued and outstanding prior to the original filing date of the registration statement of which this prospectus forms a part. The selling stockholders originally acquired the shares of our common stock included in this
prospectus through (i)&nbsp;our initial public offering or otherwise on the open market, and (ii)&nbsp;several private placements of our common stock or convertible preferred stock prior to our initial public offering, with all such shares of
convertible preferred stock converted into shares of our common stock in connection with our initial public offering. Additional information about the selling stockholders, where applicable, will be set forth in an applicable prospectus supplement,
documents incorporated by reference in this prospectus or in a free writing prospectus we file with the SEC. We will not receive any proceeds from the resale of the common stock by the selling stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the information about the selling stockholders, including the number of shares of our common stock beneficially
owned by such selling stockholders immediately prior to the date of this prospectus, the number of shares offered hereby and registered by the registration statement of which this prospectus is a part, and the number of shares of our common stock to
be beneficially owned by such selling stockholders after this offering. The number of shares to be owned after this offering assumes that all shares covered by this prospectus will be sold by the selling stockholders and that no additional shares of
our common stock are subsequently bought or sold by the selling stockholders. Except as otherwise disclosed herein and in the footnotes below with respect to the&nbsp;selling stockholder, the&nbsp;selling stockholder&nbsp;does not and within the
past three years has not had, any position, office or other material relationship with us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information set forth below is based upon
information obtained from the&nbsp;selling stockholder. The percentages of shares owned after the offering are based on 28,055,344 shares of our common stock outstanding as of December&nbsp;31, 2018, including the shares of common stock covered
hereby. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially<BR>Owned&nbsp;Prior&nbsp;to&nbsp;the&nbsp;Date<BR>of&nbsp;this&nbsp;Prospectus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Subject&nbsp;to<BR>Sale<BR>Pursuant&nbsp;to</B><br><B>this<BR>Prospectus</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially<BR>Owned&nbsp;After&nbsp;Sale&nbsp;of&nbsp;All<BR>Shares&nbsp;Subject&nbsp;to&nbsp;Sale<BR>Pursuant&nbsp;to&nbsp;
this<BR>Prospectus(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percent</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">PureTech Health LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,800,396</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,680,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,119,696</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">OrbiMed Private Investments VI, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,830,387</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,297,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quan Venture Fund I, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">667,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">467,892</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">We do not know when or in what amounts the&nbsp;selling stockholder&nbsp;may offer shares for sale.
The&nbsp;selling stockholder&nbsp;might not sell any or all of the shares offered by this prospectus. Because the&nbsp;selling stockholder&nbsp;may offer all or some of the shares pursuant to this offering, and because there are currently no
agreements, arrangements or understandings with respect to the resale of any of the shares, we cannot estimate the number of the shares that will be held by the&nbsp;selling stockholder&nbsp;after completion of the offering. However, for purposes of
this table, we have assumed that, after completion of the offering, none of the shares covered by this prospectus will be held by the&nbsp;selling stockholder. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Voting and investment power over the shares held by PureTech Health LLC is exercised by its parent entity,
PureTech Health plc. The board of directors of PureTech Health plc consists of Mr.&nbsp;Joi Ito, Dr.&nbsp;Raju Kucherlapati, Dr.&nbsp;John LaMattina, Dr.&nbsp;Robert Langer, Dame Marjorie Scarino, Dr.&nbsp;Ben Shapiro, Mr.&nbsp;Christopher
Viehbacher, Ms.&nbsp;Daphne Zohar and Mr.&nbsp;Stephen Muniz. None of the members of the board of directors of PureTech Health plc or PureTech Health LLC has individual voting or investment power
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
with respect to such shares. The address for PureTech Health LLC and the individuals listed above is c/o PureTech Health LLC, 501 Boylston St., Suite 6102, Boston, MA 02116. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">OrbiMed Capital GP VI LLC (&#147;GP VI&#148;) is the sole general partner of OrbiMed Private Investments VI,
L.P. (&#147;OPI VI&#148;). OrbiMed Advisors LLC (&#147;OrbiMed Advisors&#148;) is the managing member of GP VI. By virtue of such relationships, GP VI and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares
held by OPI VI and as a result may be deemed to have beneficial ownership of such shares. Jonathan Silverstein, a member of OrbiMed Advisors, is a member of the Company&#146;s board of directors. Advisors exercises investment and voting power
through a management committee comprised of Carl L. Gordon, Sven H. Borho and Jonathan T. Silverstein. Each of GP VI, OrbiMed Advisors, Carl L. Gordon, Sven H. Borho, and Jonathan T. Silverstein disclaims beneficial ownership of the shares held by
OPI VI, except to the extent of its or his pecuniary interest therein if any. The address of these entities is 601 Lexington Avenue, 54th floor, New York, New York 10022. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The address of Quan Venture Fund I, L.P. is Ugland House, PO Box 309, Grand Cayman, Cayman Islands <FONT
STYLE="white-space:nowrap">KY1-1104.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Relationship with Selling Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>PureTech Health LLC </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PureTech Health is a
greater than 5% stockholder and a founder of our company and in that capacity provided us with strategic medical, clinical and scientific advice pursuant to a business services, personnel and information management agreement until December 2017.
Daphne Zohar, PureTech Health LLC&#146;s founder and Chief Executive Officer, served on our board of directors until November 2018. David Steinberg is a member of our board of directors and previously served as
<FONT STYLE="white-space:nowrap">co-founder</FONT> and Chief Innovation Officer of PureTech Health, LLC until August 2018. PureTech Health LLC purchased shares of Series A preferred stock in our Series A financing in March 2017, August 2017 and
October 2017. We were a subsidiary of PureTech Health LLC until the closing of our Series B financing in November 2017. PureTech Health LLC&#146;s board designation rights terminated upon the consummation of our initial public offering. PureTech
Health LLC is entitled to the registration rights described in this prospectus under &#147;Description of Capital Stock.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>OrbiMed Private
Investments VI, LP </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OPI VI is a greater than 5% stockholder that participated in our Series B financing in November 2017, in which it
obtained the right to appoint a representative to our board of directors. Although Jonathan Silverstein was OPI VI&#146;s representative prior to our initial public offering, OPI VI&#146;s board designation rights terminated upon the consummation of
our initial public offering. OPI VI is also entitled to the registration rights described in this prospectus under &#147;Description of Capital Stock.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_12"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and/or the selling stockholders, if applicable, may sell the securities offered through this prospectus and any accompanying prospectus
supplement, if required, in any of the following ways: (1)&nbsp;to or through underwriters or dealers, (2)&nbsp;directly to purchasers, including our affiliates, (3)&nbsp;through agents, or (4)&nbsp;through a combination of any these methods. The
securities may be distributed at a fixed price or prices, which may be changed, market prices prevailing at the time of sale, prices related to the prevailing market prices, or negotiated prices. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may issue the securities as a dividend or distribution or in a subscription rights offering to our existing security holders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may directly solicit offers to purchase securities, or agents may be designated to solicit such offers. In the prospectus supplement
relating to such offering, we will name any agent that could be viewed as an underwriter under the Securities Act and describe any commissions that we must pay to any such agent. Any such agent will be acting on a best efforts basis for the period
of its appointment or, if indicated in the applicable prospectus supplement, on a firm commitment basis. This prospectus may be used in connection with any offering of our securities through any of these methods or other methods described in the
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each prospectus supplement will describe the method of distribution of the securities and any
applicable restrictions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement with respect to the securities of a particular series will describe the terms of the
offering of the securities, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name of the agent or any underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the public offering or purchase price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts and commissions to be allowed or paid to the agent or underwriters; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">all other items constituting underwriting compensation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts and commissions to be allowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any exchanges on which the securities will be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A&nbsp;selling stockholder&nbsp;that is an entity may elect to make a pro
<FONT STYLE="white-space:nowrap">rata&nbsp;in-kind&nbsp;distribution</FONT> of shares of our common stock to its members, partners or stockholders pursuant to the registration statement of which this prospectus forms a part by delivering a
prospectus. To the extent that such members, partners or stockholders are not affiliates of such&nbsp;selling stockholder, such members, partners or stockholders would thereby receive freely tradeable shares of our common stock pursuant to the
distribution through a registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any underwriters or agents are used in the sale of the securities in respect of which
this prospectus is delivered, we or the selling stockholders, as applicable, will enter into an underwriting agreement, sales agreement or other agreement with them at the time of sale to them, and we or the selling stockholders, as applicable, will
set forth in the prospectus supplement relating to such offering the names of the underwriters or agents and the terms of the related agreement with them. To our knowledge, there are currently no plans, arrangements or understandings between the
selling stockholders and any underwriter, dealer or agent regarding the sale of the shares covered by this prospectus by such selling stockholders. If any&nbsp;selling stockholder&nbsp;notifies us that a material arrangement has been entered into
with an underwriter, dealer or other agent for the sale of shares through a block trade, special offering or secondary distribution, we may be required to file a prospectus supplement pursuant to applicable SEC rules promulgated under the Securities
Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the offering of securities, we may grant to the underwriters an option to
purchase additional securities with an additional underwriting commission, as may be set forth in the accompanying prospectus supplement. If we grant any such option, the terms of such option will be set forth in the prospectus supplement for such
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a dealer is used in the sale of the securities in respect of which the prospectus is delivered, we or the selling
stockholders will sell such securities to the dealer, as principal. The dealer, who may be deemed to be an &#147;underwriter&#148; as that term is defined in the Securities Act, may then resell such securities to the public at varying prices to be
determined by such dealer at the time of resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we offer securities in a subscription rights offering to our existing security
holders, we may enter into a standby underwriting agreement with dealers, acting as standby underwriters. We may pay the standby underwriters a commitment fee for the securities they commit to purchase on a standby basis. If we do not enter into a
standby underwriting arrangement, we may retain a dealer-manager to manage a subscription rights offering for us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Agents, underwriters,
dealers and other persons may be entitled under agreements which they may enter into with us to indemnification by us against certain civil liabilities, including liabilities under the Securities Act, and may be customers of, engage in transactions
with or perform services for us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so indicated in the applicable prospectus supplement, we will
authorize underwriters or other persons acting as our agents to solicit offers by certain institutions to purchase securities from us pursuant to delayed delivery contracts providing for payment and delivery on the date stated in the prospectus
supplement. Each contract will be for an amount not less than, and the aggregate amount of securities sold pursuant to such contracts shall not be less nor more than, the respective amounts stated in the prospectus supplement. Institutions with whom
the contracts, when authorized, may be made include commercial and savings banks, insurance companies, pension funds, investment companies, educational and charitable institutions and other institutions, but shall in all cases be subject to our
approval. Delayed delivery contracts will not be subject to any conditions except that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase by an institution of the securities covered under that contract shall not at the time of delivery be
prohibited under the laws of the jurisdiction to which that institution is subject; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are also being sold to underwriters acting as principals for their own account, the
underwriters shall have purchased such securities not sold for delayed delivery. The underwriters and other persons acting as our agents will not have any responsibility in respect of the validity or performance of delayed delivery contracts.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Offered securities may also be offered and sold, if so indicated in the prospectus supplement, in connection with a
remarketing upon their purchase, in accordance with a redemption or repayment pursuant to their terms, or otherwise, by one or more remarketing firms, acting as principals for their own accounts or as agents for us. Any remarketing firm will be
identified and the terms of its agreement, if any, with us and its compensation will be described in the applicable prospectus supplement. Remarketing firms may be deemed to be underwriters in connection with their remarketing of offered securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain agents, underwriters and dealers, and their associates and affiliates, may be customers of, have borrowing relationships with,
engage in other transactions with, or perform services, including investment banking services, for us or one or more of our respective affiliates in the ordinary course of business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to facilitate the offering of the securities, any underwriters may engage in transactions that stabilize, maintain or otherwise
affect the price of the securities or any other securities the prices of which may be used to determine payments on such securities. Specifically, any underwriters may overallot in connection with the offering, creating a short position for their
own accounts. In addition, to cover overallotments or to stabilize the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
price of the securities or of any such other securities, the underwriters may bid for, and purchase, the securities or any such other securities in the open market. Finally, in any offering of
the securities through a syndicate of underwriters, the underwriting syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the securities in the offering if the syndicate repurchases previously distributed
securities in transactions to cover syndicate short positions, in stabilization transactions or otherwise. Any of these activities may stabilize or maintain the market price of the securities above independent market levels. Any such underwriters
are not required to engage in these activities and may end any of these activities at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or the selling stockholders may engage
in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In addition, we or the selling stockholders may enter into derivative transactions with third parties, or sell securities not
covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the
applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use
securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the
applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may sell the securities short using this prospectus and an
applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent offering of other securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Rule <FONT STYLE="white-space:nowrap">15c6-1</FONT> of the Exchange Act, trades in the secondary market generally are required to settle
in two business days, unless the parties to any such trade expressly agree otherwise. The applicable prospectus supplement may provide that the original issue date for your securities may be more than two scheduled business days after the trade date
for your securities. Accordingly, in such a case, if you wish to trade securities on any date prior to the second business day before the original issue date for your securities, you will be required, by virtue of the fact that your securities
initially are expected to settle in more than two scheduled business days after the trade date for your securities, to make alternative settlement arrangements to prevent a failed settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be new issues of securities and may have no established trading market. The securities may or may not be listed on a
national securities exchange. We can make no assurance as to the liquidity of or the existence of trading markets for any of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specific terms of any <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions in respect of any given offering will be described in the
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The underwriters, dealers and agents may engage in transactions with us, or perform services for us, in
the ordinary course of business for which they receive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The anticipated date of delivery of offered securities will be set
forth in the applicable prospectus supplement relating to each offer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_13"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain legal matters in connection with this offering will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Any
underwriters will also be advised about the validity of the securities and other legal matters by their own counsel, which will be named in the prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_14"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of resTORbio, Inc. and subsidiaries as of December&nbsp;31, 2017 and 2016 and for the year ended
December&nbsp;31, 2017 and the period July&nbsp;5, 2016 (inception) through December&nbsp;31, 2016, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public
accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_15">
</A>WHERE YOU CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we have filed with the
SEC.&nbsp;Certain information in the registration statement has been omitted from this prospectus in accordance with the rules of the SEC.&nbsp;We are subject to the information requirements of the Exchange Act and, in accordance therewith, file
annual, quarterly and special reports, proxy statements and other information with the SEC. These documents may be accessed through the SEC&#146;s electronic data gathering, analysis and retrieval system, or EDGAR, via electronic means, including
the SEC&#146;s home page on the Internet (<I>www.sec.gov</I>). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have the authority to designate and issue more than one class or series
of stock having various preferences, conversion and other rights, voting powers, restrictions, limitations as to dividends, qualifications, and terms and conditions of redemption. See &#147;Description of Capital Stock.&#148; We will furnish a full
statement of the relative rights and preferences of each class or series of our stock which has been so designated and any restrictions on the ownership or transfer of our stock to any shareholder upon request and without charge. Written requests
for such copies should be directed Investor Relations Department, resTORbio, Inc., 500 Boylston Street, 12<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston, MA 02116, and our website is located at<I> www.restorbio.com.</I>
Information contained on our website is not incorporated by reference into this prospectus and, therefore, is not part of this prospectus or any accompanying prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc32534_16"></A>INCORPORATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference the information and reports we file with it, which means that we can disclose important
information to you by referring you to these documents. The information incorporated by reference is an important part of this prospectus, and information that we file later with the SEC will automatically update and supersede the information
already incorporated by reference. We are incorporating by reference the documents listed below, which we have already filed with the SEC, and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act,
including all filings made after the date of the filing of this registration statement and prior to the effectiveness of this registration statement, except as to any portion of any future report or document that is not deemed filed under such
provisions, until we sell all of the securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017,
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000156459018007150/torc-10k_20171231.htm">March&nbsp;
29, 2018</A> and as amended on <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312518139320/d557670d10ka.htm">April&nbsp;27, 2018</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2018, June&nbsp;30, 2018, and September&nbsp;30, 2018, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000156459018012984/torc-10q_20180331.htm">May&nbsp;
10, 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000156459018021129/torc-10q_20180630.htm">August&nbsp;
9, 2018</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000156459018029327/torc-10q_20180930.htm">November&nbsp;13, 2018</A>, respectively; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312518025718/d483880d8k.htm">January&nbsp;30,
 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312518087835/d537800d8k.htm">March&nbsp;19, 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312518101959/d540018d8k.htm">March&nbsp;
29, 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312518156877/d584931d8k.htm">May&nbsp;9, 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000156459018012953/torc-8k_20180510.htm">May&nbsp;
10, 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312518225295/d549570d8k.htm">July&nbsp;25, 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312518231700/d592253d8k.htm">July&nbsp;
30, 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000156459018020765/torc-8k_20180809.htm">August&nbsp;9, 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312518249185/d583892d8k.htm">August&nbsp;15,
2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312518276420/d625734d8k.htm">September&nbsp;18, 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312518299732/d637736d8k.htm">October&nbsp;
16, 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312518319030/d627629d8k.htm">November&nbsp;6, 2018</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000156459018029138/torc-8k_20181113.htm">November&nbsp;
13, 2018</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312519003189/d667569d8k.htm">January&nbsp;7, 2019</A> (in each case, except for information contained therein which is furnished rather than filed); and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1720580/000119312518015584/d528214d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed with the SEC on January&nbsp;22, 2018, including any amendments or reports filed for the purposes of updating this description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon request, we will provide, without charge, to each person, including any beneficial owner, to whom a copy of this prospectus is delivered,
a copy of the documents incorporated by reference into this prospectus but not delivered with the prospectus. You may request a copy of these filings, and any exhibits we have specifically incorporated by reference as an exhibit in this prospectus,
at no cost by writing us at the following address: Investor Relations Department, resTORbio, Inc., 500 Boylston Street, 12<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Boston, MA 02116, telephone (857)
<FONT STYLE="white-space:nowrap">315-5521.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. We have
incorporated exhibits into this registration statement. You should read the exhibits carefully for provisions that may be important to you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information incorporated by reference or provided in this prospectus or any prospectus supplement. Neither we nor
the selling stockholders have authorized anyone to provide you with different information. We are not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus or
in the documents incorporated by reference is accurate as of any date other than the date on the front of this prospectus or those documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Up to $50,000,000 </B></P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g32534g44y02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Evercore&nbsp;ISI </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>H.C.&nbsp;Wainwright&nbsp;&amp;&nbsp;Co. </B></P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>December&nbsp;1, 2020 </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g32534g23a75.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g32534g23a75.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[15^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   *=V@ X0DE-!"4      ! G!5HE
M[<6#H;E>6VI=6T]S.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0%_<L(         *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M      !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG
M8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE
M9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E
M8W14;W!L;VYG       X0DE- ^T      ! #P     $  @/      0 ".$))
M300F       .             #^    X0DE- _(       H  /_______P
M.$))300-       $    >#A"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          CA"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              $T   $\
M          $                          0             !/    $T
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   $T
M    4F=H=&QO;F<   $\    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
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M&&M;]*RQQ=])%^J7_*C?^(?^6I#ZA4_H_6C92(%;Q?2.)8Z=]7_GVE6C7N$
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M6$DE/__9 #A"24T$(0      50    $!    #P!! &0 ;P!B &4 ( !0 &@
M;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O
M '  ( !# %, -@    $ .$))300B      $N34T *@    @ !P$2  ,    !
M  $   $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q  (
M   >    <@$R  (    4    D(=I  0    !    I    -  $W)S   G$  3
M<G,  "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.3HP,SHQ
M." P.3HT,#HQ,@   Z !  ,    !__\  * "  0    !   !/* #  0    !
M    30         & 0,  P    $ !@   1H !0    $   $> 1L !0    $
M  $F 2@  P    $  @   @$ !     $   $N @( !     $
M $@    !    2     $X0DE- _T       @          /_A 3!-30 J
M"  ' 1(  P    $      1H !0    $   !B 1L !0    $   !J 2@  P
M  $  @   3$  @   !X   !R 3(  @   !0   "0AVD !     $   "D
MT    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$Y.C S.C$X(# Y.C0P.C$R   #H $  P    '__P  H ( !     $
M  $\H , !     $   !-          8! P #     0 &   !&@ %     0
M 1X!&P %     0   28!*  #     0 "   " 0 $     0   2X" @ $
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M+D$I54K*@GP77<)@0.2I21Q)YQ6\\UEEV2U:,KE=3FCHW(ID;9 /L[MRIOQ
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MU'OO[) W]#V.P   XPE1'B W\A-MH -CQR;'B1)N9P1< >Q',WW=;S.WRO8
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M9_ K]U:OEW0N#"7/CK25'8+3)BLE)[[$>WJ-WII91J#)X'M5S39] X%()Y'
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M @IS9:29!F4-&PY N;$G\)(/KD%_W'=5D(44*5ISG"D*!V6%#&[)>Z=MB?F
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M3J]I:GVRIM##:'%N]80VA:EA!IE)3U555(^R!3;_ 'K>QU*2-D%)"BN!M2F
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M? U;2T]3$0.N**NEQ]QUP!?'/VH]2UVHJE*ZA:DT[:U*98!A*5$1O4 3N5M
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M.I&15CK<NKE9[/A642OFL*ZX\UF!%@0V79<900N,[,,D,K0E:$A24E)@_O\
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M0 #T 'X<98Q3R?K^I6*\&)/!]Q_#&%I*4E1"4@G;<@ $^OJ1Z_GP23R9QBD
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JQ/QM?%>#$X7!@PN#!A<&#"X,&%P8,+@P87!@PN#!A<&#"X,&%P8,?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g32534g44y02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g32534g44y02.jpg
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M  (1 0,1 ?_$ !X   ,!  (# 0$            )"@@&!P0%"P$"_\0 /!
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MA! M20;,?)JCPEF.!,V6U5GYM;A+41(#)YD,T8!,;X]UBH))"NIY4DD'(R<
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MZCZ.=<N?C-MU-4^&%IN#JHJK9U=0"GD(&_R:VW72&I@4G]V5DIYG Y)I4.<
M@U:^;@UY@ZAM[!*7"Z_YG\AJS7F61HE%_)G!A1TI0.(Y;HV.MQ@8[2,8;8'$
M.G"1F!V\);'::0RA*4-X3CCKKFDAH>K;[3P +$*TS*J\*IJHXZIU4=@JO,RA
M1PH    QK] _X:[]7]2^!/AG=KF[RUK=.1V^6:4EI9TLM7566">5VRTDLU/;
MXI9)&):1W9V)9B3C\8D@,A@L1]X4L5YH@8H9U;! Y#*TN,OL/-*2XR\RXE+C
M3K:DK;6E*T*PK&,XJJLRLK*Q5E(964D,K Y#*1@@@@$$'(/(UNV6**>*2&>.
M.:&9'BEAE19(I8Y%*O')&X*.CJ2KHP*LI((()&GT=:G97R FMN:XXX[3(?VW
M6+I(.5^&M$IAXC855<9C##!R2II&<KM$(/@-:Y9=@;)F1 E.GMSF1P,1I&ZO
M#[Q O<USH+!<BUTIZMS!%4R;FKJ8B-W5GFS_ (Q"NW^E,X:5$RXE(3RV\ZOQ
M5?A5\-J#HOJCQ1Z0CCZ+NMBIEN5=:*3RX^FKPLE7!3R0PT#86T5\AG5:-;:T
M5#-.$IVMXEJ#51TU>="Z\H-( ^HBYG_Y./#)S254EOL]G<JB9*AM)&>]AT7J
MB+:$(VC*^B%9REN:$.B*%\;R$X*"MLN^*YAZ+7E%DZ8H/:J\3N,PT8$IR.&F
M)(A7]"&D^\8!X.F%QF\J'8#AI<KWY"CXS^HPO^D=*HZGNH:(Y(=9'*'8%[AA
M!ME<H8HN!XZS,JPEIZIA:EEG):N6,8MQ*" (^\[8B50]DPC'J94*P.X*]D67
M=PN9O5[:ENU)%&Q,5&P:I53^T,RX=,=B8X6RGRD<Y^'36DHQ)32LP]Z48C)]
M IR#GG&6'/T';71_TZ?+.7XV<Q[EQ"V:Z77JYO\ =)K3$/->\156WWKY4BF)
M!)8(SA,<78XYNQ4P\=*$%2-C:IP+F59$:1AQU11+54,==#AFIL,67G?32XR1
MCN$;8X/8(9#\])VZ4Q3-"_ DXP?21<\?J,C[XU8-SHYFZTX&<=+=R#V8P5+#
M1#X<!3Z?'$,B2U]ODT@G-?J<:40VZR%]R@,Z3EI)Q@K$17HJ8ED!2#@* ":1
M;J"6XU24L)"E@6=V&5CC7&YR!R<9  &-S,HR,Y$O/,L$;2/R!P .[,>P'\R?
M0 GG&H\Q.]#N0Y'6ZPV/CAK9)54KS_W4A2--\<I3;<77HM>7' VK5/DP]PL+
M;S@S2LDR&)& 8+<0^^&$ S[1V;N>GK%2HJ54V)&'$D]4L!8]LHFY%P#V&&^1
M)U#^WUDA)C08![)&7Q]"?>.?ZOH!I>?%+:=[W?V_<=MN;0C H;8VP^;^K+3=
MXJ.BCH,*.L\IM2$>F!&(:2),/BTL&Y=0H LEY\5>%,K5C*/;B3K88Z>QU4$)
M+114$J1L6#$HL1"DL  <CU  /IIO$[/61NXPS3H6&,8)89&#R/L>?OJGOO"[
M8>5'7]N[3>NM M:RQ!7;59EUG7KM4#;)(N2R;=+P330K[-@BF1@F@XQM:6L#
M+=6^\^MQ]:/B;:J73]FH[G3SRU/F[HYA&OEN$&W8&.?=;)R=2==5RT[HL>W#
M(6.X9YR1\Q\M,VVYV)T3B_U\ZLYG;[::*FK[J74\[%T>JXQ'DWK:NQJ%'6AJ
MGU9$@^;^, 40N6D2S37C_P %6(J0D'$RA(;09L1!;)*RY2T--P(YIE,C\B.&
M*0J7? &3C:  !N=@/=!R'4E0L5.LS\DJA"CC<S ' [X]>?0:E>/[VNX+D+/6
MBZ<<M9MQFO*F\LJ6KVIN/DGMR(K$0C"B&$7BWRL+;#F2,AI]YTFA^JB$>UTD
M..C6<I9:N(Z=L=*J1U4Q,K\*TU2L#.W8^7&&0$9[#WR. 2=1?M]9(6:),*.X
M2,N%'^4Q!_KX^VJ!^H7M5O/.C1VWKMR&UD'K C0+#1-PW+"BR$5IFT13,5(3
M,R^PY-%G/U^SU*)CL2EQAVI.6 &C9"-F6WHIB18B6*S>[/%;JB&.EF,PJ<[(
M&(:>,Y"J#M #)(QQ&VU22&7#%2QD*2J:>-FD388_B?&$/<G&>Q 'O#.!G/T"
MEMF]YO87S-WK8M2]6NE%8J==P>9&S2J$'>]CSU?CRDAYN5J5:7%T+7U?DGG!
M4QT5(QSAHQ!@P15B,D"VH\>;BZ>ME!3+/>*CWWP"HD,<2.1GRTV#S)7&#E@<
M$ D( "2S:NJ)I"E*F0/FNYB <;CGA0>._P \9SKM+@CWM\E*WR@C.'?9AKZ/
MJ5EG;7&4)B_9J3FN;91;M/+%9KHFQJLA3=>,JEA?.C$!6:# @FHH62$GB%35
M?)4='HW'IVD>C-=:93(B(TACW^:DD:9WF)_B#H <HQ;<05&UAALX*Z42B&I4
M*Q(4-C:58]@P[$'(Y& ._(TIOZ@'?O(;:_,R?UQM^G)K&N-%6F]5G0LEBESE
M:5:*G.,TXR6E53DL^\)</>]&Q)&)&(2T&+@WV);2V0PE,UTU34L- LL$F^6H
M2-ZE?,5]CJ9 J[5&4X+##<G&?GII<))'F*N,+&6$9VD9!VY.3\78<C3)NE3L
M$[$+CM_B+Q/MVHVA^)(- F*J/?,:5NL:XS3J1J"TR]&EL[(=,_7%_D9R"KH&
M9-P=04O^1^S$;24<(M$3?[;:XX*VLCG_ ,=,JN8O:(VS)).BR+Y0&\85F.,Y
M7&3P#IS15%2SQ1&/^A"XW;&&%5#M.XG!R0/OGC5BWE'U,:C]^K _J7 _^]<F
MO\'0'EWZ,[W'[4G\ZG41=NT'WD_DFE5<2NQCMZT9QUU_JWC-1KE*:-JHMH;H
MTO%\92;\"MJ7N%BG[ \-;\5228E\C6F5G6UJ642T$\TY'.)3@/+*)BLM5DJ*
MJ6:JE05$A3S%-6(SD(JJ-F\%<JJ\>N<^N=-(JFL2-4B4[%SM(BW9R23S@YY)
MUU'P[N>A>2O8*SLCMBV[>TO3MNCY*>*L=:%;K5NO,82-&Q-/VU*LE1SVLM>1
MR08Z'?CX>GN08D,-F"--HD $N12O71U-);/*LL$>%C(7:Y+I&02SPJ0?.E;)
M(+/N+>\!(Q UC"8Y:C=5NP8L#R  6] YXVKVX  QQD#5C'=;SOW-P#XO:NVM
MQX11'K!<MU0&OR'[;!/62%153=?WZS97%!@2\2T@ATRMQ6&"\O$,)!R^VTQ[
MGFWFJ-8+=!<JR6&J\S:E.\HV-L;>)8DY)5N,.V1P<XYU,5L[T\*O'MR7"<C(
MP59N,$?P_P!^N1==O8=+[AZUW>;W+:8J%6142-J&7N;JT,7$0S<!1K"<$!D*
M$=D94DF:-'0+&!1X3ZWYF6=##"%488AMS&Z6Q8+K^7T2N^_R1&KL&;=(@)RV
M% 4'))/PC))P-%/4%Z;SYBHQOW$# PI('&3R>WU.I[MG]_W9+RAV=8(3@7I4
MZO4N!4\;&P%.T\=OG:I->9?4TU-WI:(NSPD4@Q*$NK#A*X&+$+=< S/S:F$R
M3MEBZ:M5)$C7*H#2-P6>=::'=ZK'DHS8[99B6[[5S@,&N%3*Q%/&0HYP$,C8
M^;8! _08^IUN7J^[^KON3=D#Q2YRT^OTO8ELG4TND;-@8<^GM.WY9&00:+LN
MER9!"86<G93_ $-%3$-^,$;GG8Z#D*T)@MV9'C[OTW'3T[5MOD:2)%\R2)V#
M_P!'W,D,B@;E5?>96W$J"P<X"E:FN#.XBG4*Q.T,!M][T5E/8D\ CUXQZZRG
MV(\4++QAW_:\)B2<:OV#.2]KUI/M,+S&+C90M<@955D)3EIF7J9)2HQX-Q>"
M7XQ$;+_&EB1;PGEGJ:SRVFY3>X?9*F1YJ60 [-KL6:$GD!X22A4G<4"R8PXU
M[-^ 7BC;O$GH2V$U49ZEL-'26OJ.A=Q[2*FFB6"&Z",X9Z6ZQQBI295\I*EJ
MFDW%Z9B6.=%VD)#,QMKD3)#+9BVHMK4U3><3GVGF%F1-HN!#6%8QZ)C6HZJB
M-$(]Z75R,@/A2%#/(5:/#Z@??6W-UPFP4<)/[S%DFG(^B[85##N6=?W3KGW\
M:W6=/[)TKT!32!ZEJENJKHJGF"**&KMEIC8C.34-4725XVP5%/3R%2)(V#X]
MS[CH.@]<67:6RIMB$J]9!=)>4M;?WLH=E"_L(*%%<<;5(SDN0E(<:"TK"GGU
M^]Q;([;[[5]NUUHK)05%RN$RPTU.A8DD;Y'P=D,*DCS)I6&R- <LQY(4$CBG
MH7H?J/Q&ZIM/2'2M!)7W>[5"11A5;R*2GW+[3<:^9584UOHHB9ZNH<$)&N%#
MRM'&\(VZ-GS.ZML[$VQ/-)'E=@VZ;L[X2',O-1K,F:Z\#$#NJ2A3@T0!D:,%
M6M.%J'$:RO'NSGSC&[W&6[W2ON<PQ)754U04!R(Q(Y*1*>Y6)-L:GN549U^A
M[H3I*AZ"Z,Z8Z-MSF2CZ:LE!:4G90CU3TE.B5%;(@)"RUM1YM7*H.T23.%XQ
MK>G$[JGY"\COQMHM8CFE]6%_"2FSV^-(S9)T%?HO#E3ICC@<@8T^VIMP>6FG
MH2&?'=P5'&2N6U#+NO3'AI?+_P"74U2FT6UL,*BJC/M$Z?\ 9J0E)&##E99C
M#$5.Z-I<;3SIXR?C$\-/"_VNT6:9.N^KX=\1M-EJH_RJWU"Y4K>;ZJSTT+QL
M&66BH(Z^NCE3R:F&CW"5:7^,?"+CYQ/C$(UE4&R+:\)]K+[(L^6)F]2R5I3@
MAO\ *J'98A0",I1EZ(KHD1%O9;:<)%()1DA70?3W2%CZ9C MU*#4E=LM?4;9
M:V4'&X>;M BC; S% L49P"RLPW:\IO%GQ]\2O&2K9NK+V\=FCF\ZBZ7M7F4/
M3]$5),;^QK([UU3$"0E;<YJRK3<ZQ311,(QK=2DI2I2E82E.,J4I6<82E.,>
MN5*SGTQC&,8SG.<Y],8_CGRSZTOKYKO:!R(V!V:=B5S:TG 6G:</"EE:>X^T
MZD1,E9Y>PTZ@8F#Y*PP$+$L$F2&+9)M6J_*>:#P4-7C V#O1F'PMO:MHI8K3
M:T-0R0LP$]2\A"!'EVA59B<#8-D>,XW XY;5;JI&JJ@B,%@N40*"20N22 /F
M<G[:U)KS<'U&NJ*)3]9:[UURUJM$H-<AZE4:Y'<0ZRH.%KT""S'1<>RZ5IH@
MLC[<0=I#A9I))QCOR%&DD%///+92P]+3222RRT;R2NSNYK),L[$LQ.)P!DGL
M  .P &E5>Y(H55F"J H A'  P!\'RTK;D/4><FH=QQG)3DEK7;VG]NWG8A.R
M8385VU>3JQZP;(K\I&60^QP8K5<KL"J;!ER(V:D,Q4>UG)Q:3RFEO%.NN3-+
M);IX&I*26">".+R6BCE\W;$RE K99FVE<J-Q/ P#QIK()T<2RJZ.S;@S)MRP
M(.1P!G.">/J=/Y[O>2!7-3K$Z^^4543AJI6K8$X'M") 4XL"K[D:I1D2; $H
MRM;C28R7KFQ1X)XU+;YL*\+(-I2U(M_)6NGZ44%WN5&_QI$#"Q&"\'F*P8?=
M6B+ ' ;(_=X?UTAGI:>4?"6.X#L'VD<_8AL?0_7ESO0=>M#&]9VI(W6LK5(Z
M;I'[EG>D>T7'B3D-?WK1.'R,[=L*<22VF6KR8B0A9:17D?-5:BP1B&QXA084
M%U''4B[3F57*R>6*<D$JT>Q0%C]/=8L&4<[R21ELE[0-'[,FW (SO&>0V3DM
M]P,@GT^VI7W-@TW:GU!E6O\ KV?C[53+'V(:Y?K]DB'DDQ,X$'LVN1N9**,1
MZLGQ9;X3SL?(C*<$D U,FB.NC/M.KMYC>'IEHY%*.MLD#(PPRDQ,<,.X(!Y!
MY!X/.HK<KW ,I!4U"X(['# <?3([]CW'&MA_5/\ ^M7QN_[?#/\ R/:?&71_
M_ ZO_P 2/]DFEKK^UB_[L_ZQU[3O<C+F[U\=/$R&DO.O =(1L985M8<P W<Y
M726D"J:DW./5I1;T'#WO,9C/HXEEB7]ON2M7MPZ;:/\ ,KVIQYIF+)\_+6>H
M$F/IN:+/U*_KE< WL](1\(7!^Y1,9Y^0../GSI^/1K?^/TOUKZ+C-12]4#,H
MU<D!]U1 I<>-.0.SLR<B7<)>[#Y<0:,Y-NI_,Q$G*XPT35G(C ;_ ./$89'K
MO4$=2MUJ3.'(D<&!B"5:' \M8SR"%'NL%[.&R 2=/J%HS31A",A??'&0V3N+
M#ZGD$^F->DYK;HT%R ZQ>P."X1WS6US<H5%V*#?HK468YAF,,S)*L6SC"8Z)
M&"2>/:H!FXR&;2$P9#W-:I<V/EYA237<94%/4TUVMC5\<L8DEA,;3Y]X8V0@
M%LX*-L&PX9/=!"C&OD[QR4U0(&5BJN&"XX]7R..XR<^I[$ZE*Z9M <G^0,WN
MFK\2^<\9Q,V$.)4I&R4W)4\#8MF5D',\D.;B\0N/DEH^FG'&#2K",.*B7+$
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M*M5J(L%P$4E><R!CCL>X&T'Y$8)SVNWW96-2VG6%P&WC 5RPZRB822L=I'M
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MEML^F;FT7NV8KENI\70X^>B+!K._@"$"3%W@)FPCJ:CYAS,722XU#0!@:R(
MEB4'+BY23CI&2N%^2>LI*^BBDIZFG5DD,A5EEC)RL;*IY7WI V2#AA@@J"&\
M%$4BD@E97C<AAM!!5NQ()S@\#'V^1.E)73Z6GE%'7@P+6')32$OK(LI;*)VY
M-;!J=V1#K>PYAD^I5^K6Z!D"F$81C*47$04U]K#V41Z5X;:FX^L*0Q@S4E0)
M@.5C,3Q[OF'9T8 _YA([<]]-&M<H8A)4VGU;<&Q]0 1_?K<>GOIOE<?N17#S
M=NO.1 DZQI*X4G8&YQ[96"PR[K::;>,6I*]>Q\626-7H@^):!KJ0)V7DB W8
M_,VL\UR0=CAHZ?JGVJEKJ>6E*FH1XX"C@B-'C"8E+ %F#9?*@9W;<#;DKI;?
M+EAD63.PJSAARQ#9]W'88P,'Y9SSK2O<#TY[1[(MNZIV9K[<%!UV-0=<%T62
MB;E#V(U\U]RSR4^Q(@E0C9#?PJ;DUC.COLLK:6.EQ#CR7\I8:V.^0VJ&:*6"
M24RRB0-&R@ ! I!#8^6<CY^F.5*RC:I=&5U7:I4@@GU)SQ]],ENO!35.Z^$5
M(X5;[&3<ZQ6-3:UH+UDA4_AYB,M6N:E%5Z,V!3"24'N04T&;'NG1WW"#AW B
MRH69&E(<^3 ,B8[A-3U[U],?+=II9 K>\I25RQCD P&4@X/;D!E(8 ATT"20
MB&0;E"JI(X.5  (/H<CC^H\9U+'L;Z6GD_%VX\?3/)+2%AH!3[C8\AL1.P:)
M;6XQQW#B19&$JU2O\-(/#HPA#CS4\&P<\TDC 8"7,,,7"+K"D* STDZR@#B(
MQ2)N]2&=XV4'N!M)';)[F*:UR@^Y*A4_Q;E./L P/]8T^WJPZ@=;]=%4N\C/
M6M&XMR[7@V*S?K,_$9C*8%4$.Y+=H]:K)9!ZRHDPS*7IV6G77BY]0@.$1L((
MTY'NUR\7N6Z/&%3R((6+1(&RY<\>8[@## <*J\+SRQ.=/Z6C6F#$G>[C#'&%
MQ_"!\B>Y/?CMI3G+;Z9:R'[1E-D<%=VU+74)+2I$R#K7:)5OA$T$HEU;SH=-
MV'38BU2Y4(RIY;,/'RU>8DXH)ML4FQ3*LY(3,T?5BB$17&G>9@-IEB"'S .Q
MDBD*KN_B(;:QY"KII+;"7+02!0>=K9&WYX903CY CCMGY=]=9?0?M?BAR)K7
M*7D!R89F+Y3WI$F-J&F#;.]&68B6 (CC6;]?;A&P4S.UX@4AQ,A5V*J-B4?2
M,Z1.H8%6(6WNW4<-;2M1TU)MB?&7G";DVG(\J-"RJP(X?><#("\Y"E-0-%()
M9)=S#. A."3D'<QP2".XQSZG6[^X7JV([+=8ZW8I=XA-?[ATU+V0VDREK%D7
MZA.0MT&AF+16K"_##FR\5A\FMUV3C9L*,FU N1Q82H=]$NX6%'6.\?E,TIDC
M:6"=5$BH0'5HRQ1UW$*<!V5E)7.0=WNX*]92^THN&"NA)4D<$'&0<<CL"",X
MQVYX5KUR_3W\F.*7*+4O)/9?([4\0]JBQO3::SJF-N-Q*M<:=%2,!-UDR;M4
M1KMF"#GH.6D(PXYJ*G7&ABG4M!J<4EUN7NG4U)6T<])%23'SE"[YF1 A#!E<
M*ADW%64$#<N<<G'&FM-;Y(94D:1?<.<(&.>XP20N,CZ'^[FM/RF:EM)*[DNK
M#8G9B%QY;U]M*EZV(TL5M1<FBY14Y(,S;.Q&M>)'4"]"(>6,[&+H[N'FR&%(
M)1(MJ;=:R,I#T_8KQ%:35>;#)*)Q#CRV4%3$9<Y#=\^9Z'C'UX95E*U2(PKA
M=A;.03G=M^7RQI&_\U;Y*?\ ,_H[_P"/7W_\_P L/^&-)_T.H_MQ_P"_3'\J
MD_YU/[+:VEQ&^F'UGKF\0M[Y7;G1NV/@3AY$;4U*K!54I<P4&ZEYEFX623E3
MIZ?@G58Q]W Q<75U$_&EHN6*!>) >85O5LTL;1T<'LY8$>=(X>101C**%"HW
MR8L^.X&<$+0VQ48-*^_'.P#:"?J<DD?08SZ\=VE=MG75:>P_CCKG2.M;Q3]6
M&:_VQ!7\9^Q0\B1 .0L12+I4,080T CY8];/[,&\&EL58B!@G!L)9]S2L0]E
MNB6NKEJ)8WF$D#1$(P#!FDCDW$MW^ @\@Y.>=.ZNG-1$L:L$VN&Y!(P%9<<=
MOB_NUS7KYX M<5."P_#7=4I4=R1DL_LT>\-@Q1[%3L%>V-*R3ID L.44@Y\=
M<0;]J6\M J_F<=^WPCXFGUIW.Y>V7$U\"O 5\DQY8%U:)0 V5X!W#([_ %U]
MIZ?RH!"Y#CWMW'!#$\8/T/.I]N2/TNFRV[_*3?#_ ']06*#*&DDQU3W<1;X"
MQU ,M2TJAF+?2JQ<F[:(.VM30YIT)735!Y2,<F0);=D#+-2]7Q>4JUU-(9
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4:/#1H\-&CPT:/#1H\-&CPT:__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g32534g96z51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g32534g96z51.jpg
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M@92AHQDS0U5S@I:BL;+!U @)&#4W5E=R=7>TMM4D8I6S\"6#X?'_V@ , P$
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MW'S&]:>]6$L//,[58SUQ/=/G-0$=ZQA(GTC9_!1/_M"Q34?7H8?RA.;7WO\
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MCHR$=<X&K2G6E* S%@8/H>V@ZB>*.Y&4^SMV*R6LX'DGJ0X^FXZO 2--%W8
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M'9&QSU:B5LUTJ+(D@5'-2 W,Q6$-Q%=W,MTML(KAHAO5"C,;:XN$!)E1R7>
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M)H;II)7CFMPI2/EJT<C&6.,Q&3F K(5:210L;@K Y.%)9,S,P9  "K$@G)!
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M30NPNI.!-S)'G:=0K23Q[V4 S,0HYX1MSSR.PD20%CG'5MU#%U7"JH4D@*V
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MLAA1MVZ4^"P^ GX2E<_MGBSFK'>>F%'53\(GL(/FCR5NWK;J-^0'"?WO7O\
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MG6X*"$)<7"][.9(,*@Y4C,&+I]\\%BRJVX=<JI\0Q4J3NRB'>,-X1\(#(P?
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M%NM:(8X[L4G'LH4XZ]$"$%OZ&(:0$_D-LX.%RQ*QL!C&>9R]H!)Q^ZH#XMQ
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M$8*ZA\4L0IA;;XQ(S[:'F'V5H=9=0AQM:5IUO5E9D971F1T8,CJ2K*RG*LK
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MKY6<<ZDA#AA3B"UM.%I60\M)3C&E:8<(2I>]/+9TM>FEN:4IO2U:1O7=OQ8
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MDR%L!PBX\/(YC]BSUO?]&XU^\$/\!GAOW->)_167YXON5^B7^71W!?CO%/\
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MF8L2:OLM6O3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I4)L?Q&R?\
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M:=]/YJ_I]M/;4\J>Y;C_ .O;'_KC[6(/C4OT:>VG?3^:OZ?;3VU/*GN6X_\
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M[EE18V35))2X.X-$B@88D<^>WPY8^;_QY]JK)^%SR/[K%]^]%I^<3>Y7V_\
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M/^6FI_\ =/"-<'Y\M5^Q],4IBE,4IBE,4IBE,4IBE?N)^S%_9BD\U$PO4!U
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M/YZQ]R:?]_(OS!_[W3]D6T?_ &5:E_*VU_\  4]@+:OG.5_[K)'\]8^Y-/\
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M0TE+BD;=SJ5C:6)U.YN$BL1'#*;E@Y3EW#1I"V%4OB1I8P/!R-PR ,XZ]HG
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MP/W&^Z;W2;"\U/@?A&_XAL+"[%A>7-I-81)!=F&.XY#"[N[=RW)ECDRJLN'
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MZE8VEB=3N;A(K$1PRFY8.4Y=PT:0MA5+XD:6,#P<C<,@#..O:)P-Q9Q)Q8O
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MYVL#T!'7MK;XX[G/&W<VOK/3...'[OAZ^U"T-]9VUW+:2O/:":2W,ZFTN+A
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MJ<V(2P]W-MK;[7-:[^[2DZIINKZ=K$4DVFW27<44G*D>-9%"R;0^TB1$.=K
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M0>3VN&*;R_7Y[D]Z3L,,U4!0K W(+DZH%*2%A$T^5#L1_F1@4)*$/*V9IM:
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MM$1\B\TSW*7Y33I@[RVV^]2E^6A6D]RE*\/'>]Y,D$$I!EABE(& 9(T<@=N
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M0 3CIDU:\U"_U!TDO[V[OI(UV))>7,URZ)DML1IG=E7<2=H(&23C)JR$J%3
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M"F2&6_)9?EHB/D7FF>Y2_*:=,'>6VWWJ4ORT*TGN4I7AX[WO)D@@E(,L,4I
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M";47$QK7'4G?/7$P''B-%.1O$<MRTF(C!TSKJI31\9$.CAE O/&M@E!34C#
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MYXTK?%/&$*W"U:MB^6C:NQV2F))[2525@GC4MM*DIR7(3LD\Q:$)\?+&$9%
M&$$'^F-+TRST>RAL+&/EP0+@9ZO(YZO+*V!OED;PG; '8JA455'X0\>\=\2]
MTGBG5.+^*[]K[5]4EW-C<EK96J$BVT[3H&=Q:Z?9QGE6\"LQQNEF>6XEFFDE
MG.0KIU,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IB
ME,4IBE,4IBE,4IBE,4J$V/XC9/\ DG!_X[L.9?W ?PI_J+5?P_XO]M39F*K4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5\K0AQ*D.)2M"M>"D+3I25:_\
MDI.];UO7_P##>L4JU]71_P#<0_HS'^S)R?*?6:4]71_]Q#^C,?[,9/E/K-*>
MKH_^XA_1F/\ 9C)\I]9I3U='_P!Q#^C,?[,9/E/K-*>KH_\ N(?T9C_9C)\I
M]9I3U='_ -Q#^C,?[,9/E/K-*>KH_P#N(?T9C_9C)\I]9I3U='_W$/Z,Q_LQ
MD^4^LTIZNC_[B']&8_V8R?*?6:4]71_]Q#^C,?[,9/E/K-*>KH_^XA_1F/\
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MK_\ =-__ ."?],C \@]0J=[^<WSC[:^DH0CQ[4I3X_\ 'M3K7C__ #\-:R<
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M.:+#I<5(3-C8C'ASCXX*,%)-,V\&V_IQ#[8P9;B!W.QY[8[C;*''=:1N I)
M["Q &>S)[*=E:C(\S4V+C[5(%>M=:I!$ZS: T@HT?%MP$%,V,D[0SA+:CXPR
M+@)?<7(QBC0SC8\R+;=U)!&"CR(V) &/"QCKVY('K!(R.T YQ2MOB+C!R\I(
MP*"% 6*)=0W(5^2\H:5:2Z*P:R4.TEUUB2CW1B65HDHH@Z/2[YP3A+9XA@H\
M%2 #V@^,=GDZ^0_B.#X^S%*@\OJUX@BYL^MSQ%FK<Y&6U53.C;!69"+('_\
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M4J4+5_!=??\ N@X/_P J.HK/!.[W_F/1O^*C_I+ROOG_ !=W^F+BS_EIJ?\
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J[=^7&/Z!48&<^/&/R5L.5J:8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
